129 results on '"Catino A"'
Search Results
2. Prognostic factors for survival in extensive‐stage small cell lung cancer: An Italian real‐world retrospective analysis of 244 patients treated over the last decade
- Author
-
Vito Longo, Pamela Pizzutilo, Annamaria Catino, Michele Montrone, Francesco Pesola, Ilaria Marerch, and Domenico Galetta
- Subjects
Pulmonary and Respiratory Medicine ,Oncology ,General Medicine - Abstract
Potential relationships with the prognosis of patients with extensive-stage non-small cell lung cancer (ES-SCLC) have been investigated without valid results.A retrospective analysis of real-world data of consecutive patients with ES-SCLC admitted to our Medical Thoracic Oncology Unit was carried out from 2010 to 2020, focusing on identification of prognostic factors. Kaplan-Meier analysis was used to represent progression-free survival (PFS) and overall survival (OS). Univariable and multivariable Cox models were used to investigate prognostic factors.The analysis included 244 patients. The median OS was 8 months (95% confidence interval [CI]: 8-10) and the median PFS was 5 months (95% CI: 5-6). The univariable analysis showed that factors associated with shorter OS were older age (p = 0.047), TNM stage 4 versus 3 (p 0.001), Eastern Cooperative Oncology Group (ECOG) performance status (PS) 1 and 2 versus 0 (p 0.001), and2 metastatic sites (p = 0.004). Mediastinal radiotherapy (RT) (p 0.001),1 irradiated site (p = 0.026), 3 and 4 chemotherapy (CT) lines versus 1 (p = 0.044 and 0.001, respectively), prophylactic cranial irradiation (PCI) (p 0.001), and surgery (p = 0.001) correlated with longer OS. The multivariable analysis revealed statistically significant associations for TNM, ECOG PS 2 versus 0, number of CT lines, PCI, and surgery. A total of 23 patients (9.4%) survived ≥24 months, 39% of whom had received four CT lines and 48% had mediastinal RT.Our data suggest that tumor burden, PS, and mediastinal RT strongly correlate with outcome. With the addition of immunotherapy to CT, the identification of new biomarkers as predictive factors is urgently required.
- Published
- 2022
3. Controversial role of mast cells in <scp>NSCLC</scp> tumor progression and angiogenesis
- Author
-
Vito Longo, Annamaria Catino, MIchele Montrone, Domenico Galetta, and Domenico Ribatti
- Subjects
Pulmonary and Respiratory Medicine ,Lung Neoplasms ,Neovascularization, Pathologic ,Oncology ,Carcinoma, Non-Small-Cell Lung ,Tumor Microenvironment ,Humans ,Mast Cells ,General Medicine - Abstract
Mast cells (MCs) are multifunctional immune cells implicated in both physiological and pathological processes. Among the latter, MCs play a crucial role in cancer. Many studies have shown a correlation between MCs and tumor progression in several solid and hematological malignancies. In particular, MCs can directly promote tumor growth via c-kit/stem cell factor-dependent signaling and via the release of histamine, which modulate tumor growth through H1 and H2 receptors. At the same time, MCs can increase tumor progression by stimulating angiogenesis via both proangiogenic cytokines stored in their cytoplasm, and by acting on the tumor microenvironment and extracellular matrix. With regard to NSCLC, the role of MCs has not yet been established, with studies showing a correlation with a poor prognosis on the one hand and suggesting a protective effect of MCs on the other hand. These controversial evidences are at least, in part, due to the heterogeneity of the studies exploring the role of MCs in NSCLC, with some studies describing only the MC count without specification of the activation and degranulation state, and without reporting the intratumoral localization and the proximity to other immune and cancer cells. A better knowledge of the role of MCs in NSCLC is mandatory, not only to define their prognostic and predictive proprieties but also because targeting them could be a possible therapeutic strategy.
- Published
- 2022
4. Smoking status during first-line immunotherapy and chemotherapy in NSCLC patients: A case-control matched analysis from a large multicenter study
- Author
-
Maria Vittoria Pensieri, Ettore D'Argento, Giovanni Mansueto, Lorenza Landi, Mario Occhipinti, Diego Cortinovis, Robin Cornelissen, Diego Signorelli, Lorenzo Antonuzzo, Gabriele Minuti, Valerio Maria Napoli, Corrado Ficorella, Francesco Grossi, Raffaele Giusti, Cinzia Baldesarri, Vincenzo Di Noia, Giampiero Porzio, Alfredo Addeo, Luigi Della Gravara, Vincenzo Sforza, Serena Ricciardi, Paola Bordi, Francesca Rastelli, Alessandro Inno, Giuseppe Luigi Banna, Giovanni Rossi, Michele De Tursi, Matteo Santoni, Rita Chiari, Alessandro De Toma, Olga Nigro, Andrea De Giglio, Clelia Donisi, Luca Cantini, Fabrizio Citarella, Alessio Cortellini, Michele Montrone, Alain Gelibter, Gianmarco Leone, Alessandro Follador, Annamaria Catino, Federica Zoratto, Marco Filetti, Pietro Di Marino, Giulio Metro, Alex Friedlaender, Alessandro Leonetti, Rossana Berardi, Maria Rita Migliorino, Marco Russano, Katia Cannita, Pulmonary Medicine, Cortellini A., De Giglio A., Cannita K., Cortinovis D.L., Cornelissen R., Baldessari C., Giusti R., D'Argento E., Grossi F., Santoni M., Catino A., Berardi R., Sforza V., Rossi G., Antonuzzo L., Di Noia V., Signorelli D., Gelibter A., Occhipinti M.A., Follador A., Rastelli F., Chiari R., Gravara L.D., Inno A., De Tursi M., Di Marino P., Mansueto G., Zoratto F., Filetti M., Montrone M., Citarella F., Pensieri M.V., Russano M., Cantini L., Nigro O., Leonetti A., Bordi P., Minuti G., Landi L., De Toma A., Donisi C., Ricciardi S., Migliorino M.R., Napoli V.M., Leone G., Metro G., Banna G.L., Friedlaender A., Addeo A., Ficorella C., and Porzio G.
- Subjects
Male ,non‐small cell lung cancer ,0301 basic medicine ,Pulmonary and Respiratory Medicine ,Oncology ,medicine.medical_specialty ,Lung Neoplasms ,medicine.medical_treatment ,First line ,Respiratory System ,Pembrolizumab ,immunotherapy ,non-small cell lung cancer ,pembrolizumab ,smoking ,tobacco ,lcsh:RC254-282 ,03 medical and health sciences ,0302 clinical medicine ,SDG 3 - Good Health and Well-being ,Carcinoma, Non-Small-Cell Lung ,Internal medicine ,medicine ,Humans ,Chemotherapy ,Science & Technology ,business.industry ,Hazard ratio ,Original Articles ,General Medicine ,Immunotherapy ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Former Smoker ,Survival Analysis ,Lung Neoplasm ,030104 developmental biology ,Case-Control Studies ,030220 oncology & carcinogenesis ,Cohort ,Female ,Original Article ,Smoking status ,Case-Control Studie ,business ,Life Sciences & Biomedicine ,Human - Abstract
Background Improved outcome in tobacco smoking patients with non‐small cell lung cancer (NSCLC) following immunotherapy has previously been reported. However, little is known regarding this association during first‐line immunotherapy in patients with high PD‐L1 expression. In this study we compared clinical outcomes according to the smoking status of two large multicenter cohorts. Methods We compared clinical outcomes according to the smoking status (never smokers vs. current/former smokers) of two retrospective multicenter cohorts of metastatic NSCLC patients, treated with first‐line pembrolizumab and platinum‐based chemotherapy. Results A total of 962 NSCLC patients with PD‐L1 expression ≥50% who received first‐line pembrolizumab and 462 NSCLC patients who received first‐line platinum‐based chemotherapy were included in the study. Never smokers were confirmed to have a significantly higher risk of disease progression (hazard ratio [HR] = 1.49 [95% CI: 1.15–1.92], p = 0.0022) and death (HR = 1.38 [95% CI: 1.02–1.87], p = 0.0348) within the pembrolizumab cohort. On the contrary, a nonsignificant trend towards a reduced risk of disease progression (HR = 0.74 [95% CI: 0.52–1.05], p = 0.1003) and death (HR = 0.67 [95% CI: 0.45–1.01], p = 0.0593) were reported for never smokers within the chemotherapy cohort. After a random case–control matching, 424 patients from both cohorts were paired. Within the matched pembrolizumab cohort, never smokers had a significantly shorter progression‐free survival (PFS) (HR = 1.68 [95% CI: 1.17–2.40], p = 0.0045) and a nonsignificant trend towards a shortened overall survival (OS) (HR = 1.32 [95% CI: 0.84–2.07], p = 0.2205). On the contrary, never smokers had a significantly longer PFS (HR = 0.68 [95% CI: 0.49–0.95], p = 0.0255) and OS (HR = 0.66 [95% CI: 0.45–0.97], p = 0,0356) compared to current/former smoker patients within the matched chemotherapy cohort. On pooled multivariable analysis, the interaction term between smoking status and treatment modality was concordantly statistically significant with respect to ORR (p = 0.0074), PFS (p = 0.0001) and OS (p = 0.0020), confirming the significantly different impact of smoking status across the two cohorts. Conclusions Among metastatic NSCLC patients with PD‐L1 expression ≥50% receiving first‐line pembrolizumab, current/former smokers experienced improved PFS and OS. On the contrary, worse outcomes were reported among current/former smokers receiving first‐line chemotherapy., Improved outcome in tobacco smoking NSCLC patients following treatment with immune checkpoint inhibitors (ICIs) has previously been reported. Little is known regarding this association during first‐line immunotherapy in patients with high PD‐L1 expression. Clinical outcomes according to the smoking status of two large multicenter cohorts were compared in this study. Smokers with high PD‐L1 expression ≥ 50% experienced improved progression‐free survival (PFS) and overall survival (OS) with first‐line pembrolizumab. The opposite trend was found in NSCLC patients treated with first‐line platinum‐based chemotherapy.
- Published
- 2021
5. Successful treatment of triple EGFR mutation T785A/L861Q/H297_E298 with afatinib
- Author
-
Arsela Prelaj, Vito Longo, Michele Montrone, Annamaria Catino, Iolanda Capone, Pamela Pizzutilo, Domenico Galetta, Ilaria Marech, and F. Pesola
- Subjects
0301 basic medicine ,Pulmonary and Respiratory Medicine ,Male ,Lung Neoplasms ,Afatinib ,Case Report ,Case Reports ,medicine.disease_cause ,03 medical and health sciences ,Exon ,0302 clinical medicine ,Carcinoma, Non-Small-Cell Lung ,medicine ,Humans ,kinase inhibitors ,Epidermal growth factor receptor ,Tyrosine ,Non-Small-Cell Lung ,Protein Kinase Inhibitors ,RC254-282 ,Mutation ,biology ,business.industry ,Carcinoma ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,General Medicine ,Middle Aged ,compound EGFR mutations ,respiratory tract diseases ,ErbB Receptors ,030104 developmental biology ,Oncology ,Egfr mutation ,030220 oncology & carcinogenesis ,uncommon EGFR mutations ,Cancer research ,biology.protein ,Non small cell ,business ,Tyrosine kinase ,tyrosine ,medicine.drug - Abstract
Patients with non‐small cell lung cancer (NSCLC) and uncommon epidermal growth factor receptor (EGFR) mutation are characterized by high heterogeneity, and globally considered to have a worse prognosis than patients with the two common mutations; exon 19 deletion, and exon 21 L858R. Nevertheless, some uncommon mutations do confer sensitivity to tyrosine kinase inhibitors (TKIs) which is comparable with common mutations. In particular, some compound EGFR mutations seem to be characterized by a favorable prognosis. Unfortunately, the rarity of complex EGFR mutations results in difficult clinical decision‐making. Herein, to the best of our knowledge, we report the first case of an NSCLC patient with an EGFR triple mutation containing T785A/L861Q/H297_E298 who was successfully treated with afatinib., Patients with NSCLC and uncommon EGFR mutation are globally considered to have a poor prognosis. Nevertheless, some uncommon mutations confer sensitivity to tyrosine kinase inhibitors. In particular, some compound EGFR mutations appear to be characterized by a favourable prognosis. Herein, we report the first case of an NSCLC patient with an EGFR triple mutation containing T785A/L861Q/H297_E298 successfully treated with afatinib.
- Published
- 2021
6. P2.10-05 Circulating CD3+CD56+ Cells as a Biomarker for Immunotherapy in SCLC
- Author
-
V. longo, A. negri, S. De Summa, P. Pizzutilo, A. Catino, M. Montrone, S. Montagna, F. Pesola, I. Marech, N. Varesano, G. Del Bene, A. Perrone, M. Gesualdo, P. Petrillo, A. Guarini, and D. Galetta
- Subjects
Pulmonary and Respiratory Medicine ,Oncology - Published
- 2022
7. Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study
- Author
-
Alessandro Lazzarin, Rossana Berardi, Simone Scagnoli, Federica Cecchi, Sergio Bracarda, Luigia Stefania Stucci, Giampiero Porzio, Marco Russano, Pietro Di Marino, Marco Tucci, Francesco Spagnolo, Ilaria Vallini, V. Adamo, Biagio Ricciuti, Graziella Pinotti, Rita Chiari, Laura Pala, Melissa Bersanelli, Nicola Battelli, Alessandro Russo, Paolo Marchetti, Domenico Galetta, Olga Nigro, Fabio Conforti, Mariangela Torniai, Monica Giordano, Matteo B. Suter, Michele Ghidini, Corrado Ficorella, Erika Rijavec, Annamaria Catino, Alessio Cortellini, Michele De Tursi, Raffaele Giusti, Paola Bordi, Marco Filetti, Federica De Galitiis, Andrea De Giglio, Paola Queirolo, Alessandro Tuzi, Serena Macrini, Maria Concetta Fargnoli, Andrea Botticelli, Daniele Santini, Enrica Teresa Tanda, Pamela Pizzutilo, Elena Bolzacchini, Matteo Santoni, Rosa Rita Silva, Francesca Di Pietro, and Marianna Tudini
- Subjects
Male ,Oncology ,0301 basic medicine ,Cancer Research ,Immune checkpoint inhibitors ,Pembrolizumab ,Antineoplastic Agents, Immunological ,0302 clinical medicine ,Immune-related adverse events ,Neoplasms ,Atezolizumab ,Aged, 80 and over ,biology ,Middle Aged ,Prognosis ,Treatment period ,Survival Rate ,Nivolumab ,030220 oncology & carcinogenesis ,Female ,Immune checkpoint ,Immunotherapy ,Adult ,medicine.medical_specialty ,Drug-Related Side Effects and Adverse Reactions ,Side effect ,03 medical and health sciences ,Immune system ,PD-L1 ,Internal medicine ,medicine ,Humans ,In patient ,Adverse effect ,Survival rate ,Aged ,Retrospective Studies ,business.industry ,Disease progression ,Retrospective cohort study ,medicine.disease ,030104 developmental biology ,Multicenter study ,biology.protein ,business ,Adverse drug reaction ,Follow-Up Studies - Abstract
Data on spectrum and grade of immune-related adverse events (irAEs) in long-term responders to immune checkpoint inhibitors (ICI) are lacking.We performed a retrospective multicenter study to characterized irAEs occurring after a 12-months minimum treatment period with PD-(L)1 ICIs in advanced cancer patients. IrAEs were categorized into “early” (≤12 months) and “late” (>12 months).From September 2013 to October 2019, 436 consecutive patients were evaluated. 223 experienced any grade early-irAEs (51.1%), while 132 experienced any grade late-irAEs (30.3%) (p < 0.0001). Among the latter, 29 (22%) experienced a recurrence of an early-irAEs, while 103 (78%) experienced de novo late-irAEs involving different system/organ. Among patients with late-irAEs, 21 experienced G3/G4 irAEs (4.8%). Median time to onset of early-irAEs was 3.4 months (95%CI: 2.8-4.2), while the median time to onset of late-irAEs was 16.6 months (95%CI: 15.8-17.6). Cumulative time-adjusted risk of disease progression according to both the early-irAEs (HR = 0.63 [95%CI: 0.30-1.29], p = 0.204) and late-irAEs occurrence revealed no statistically significant differences (HR = 0.75 [95%CI: 0.37-1.56], p = 0.452). Also the time-adjusted cumulative risk of death according to both early-irAEs (HR = 0.79 [95%CI: 0.34-1.86], p = 0.598) and late-irAEs (HR = 0.92 [95%CI: 0.49-1.74], p = 0.811) did not show statistically significant differences.Although less frequent than early-irAEs, late-irAEs are quite common in long responders to PD-(L)1 ICIs, and are different in terms of spectrum and grade. Time-adjusted analysis revealed that the cumulative risk of disease progression and death were not significantly reduced in patients who experienced late-irAEs.
- Published
- 2020
8. Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression >= 50% and Their Relationship With Clinical Outcomes
- Author
-
Raffaele Giusti, Giorgia Guaitoli, Mario Occhipinti, Diego Cortinovis, Ornella Cantale, Luca Cantini, Cinzia Baldessari, Alessio Cortellini, Francesco Grossi, Linda Pettoruti, Vincenzo Sforza, Giovanni Mansueto, Francesco Passiglia, Francesca Mazzoni, Lorenza Landi, Alain Gelibter, Melissa Bersanelli, Daniele Santini, Paolo Marchetti, Alessandro Morabito, Alessandro Leonetti, Marianna Tudini, Serena Ricciardi, Fabrizio Citarella, Ettore D'Argento, Francesca Rastelli, Matteo Santoni, Vincenzo Di Noia, Giampiero Porzio, Robert A. Belderbos, Claudia Proto, Simona Scodes, Marianna Macerelli, Marco Filetti, Joachim G.J.V. Aerts, Diego Signorelli, Luigi Della Gravara, Carlo Genova, Danilo Rocco, Lorenzo Antonuzzo, Alessandro Tuzi, Cristina Cecchi, Luca Sala, Corrado Ficorella, Marco De Filippis, Giuseppe Luigi Banna, Alessandro Inno, Mariangela Torniai, Pamela Pizzutilo, Emilio Bria, Maria Giovanna Dal Bello, Domenico Galetta, Federico Cappuzzo, Federica Bertolini, Rossana Berardi, Maria Rita Migliorino, Miriam Grazia Ferrara, Clelia Donisi, Rita Chiari, Alessandro De Toma, Olga Nigro, Michele Ghidini, Annamaria Catino, Alfredo Addeo, Federica Zoratto, Alessandro Follador, Pietro Di Marino, Alex Friedlaender, Marco Russano, Biagio Ricciuti, Katia Cannita, and Pulmonary Medicine
- Subjects
0301 basic medicine ,Pulmonary and Respiratory Medicine ,Oncology ,Adult ,Male ,PD-L1 ,Cancer Research ,medicine.medical_specialty ,Lung Neoplasms ,Drug-Related Side Effects and Adverse Reactions ,First line ,irAEs ,NSCLC ,Pembrolizumab ,Immune checkpoint inhibitors ,Antibodies, Monoclonal, Humanized ,B7-H1 Antigen ,03 medical and health sciences ,0302 clinical medicine ,Immune system ,Antineoplastic Agents, Immunological ,Internal medicine ,Carcinoma, Non-Small-Cell Lung ,medicine ,Humans ,Adverse effect ,Lung cancer ,Aged ,Retrospective Studies ,Aged, 80 and over ,biology ,business.industry ,Middle Aged ,medicine.disease ,Prognosis ,Survival Rate ,030104 developmental biology ,030220 oncology & carcinogenesis ,Cohort ,biology.protein ,Carcinoma, Squamous Cell ,Pd l1 expression ,Female ,business ,Follow-Up Studies - Abstract
The role of immune-related adverse events (irAEs), as a surrogate predictor of the efficacy of checkpoint inhibitors, has not yet been described in the setting of first-line, single-agent pembrolizumab for patients with metastatic non-small-cell lung-cancer (NSCLC) with a programmed death-ligand 1 (PD-L1) expression of ≥ 50%.We previously conducted a multicenter retrospective analysis in patients with treatment-naive metastatic NSCLC and a PD-L1 expression of ≥ 50% receiving first-line pembrolizumab. Here, we report the results of the irAE analysis and the potential correlation between irAEs and clinical outcomes.A total of 1010 patients were included in this analysis; after a 6-week landmark selection, 877 (86.8%) patients were included in the efficacy analysis. Any grade irAEs (P .0001), grade 3/4 irAEs (P = .0025), leading to discontinuation irAEs (P = .0144), multiple-site and single-site irAEs (P .0001), cutaneous irAEs (P = .0001), endocrine irAEs (P = .0227), pulmonary irAEs (P = .0479), and rheumatologic irAEs (P = .0018) were significantly related to a higher objective response rate. Any grade irAEs (P .0001), single-site irAEs (P .0001), multiple-site irAEs (P = .0005), cutaneous irAEs (P = .0042), endocrine irAEs (P .0001), gastrointestinal irAEs (P = .0391), and rheumatologic irAEs (P = .0086) were significantly related to progression-free survival. Any grade irAEs (P .0001), single-site irAEs (P .0001), multiple-site irAEs (P = .0003), cutaneous irAEs (P = .0002), endocrine irAEs (P = .0001), and rheumatologic irAEs (P = .0214) were significantly related to overall survival.This study confirms the feasibility and the safety of first-line, single-agent pembrolizumab, in a large, real-world cohort of patients with NSCLC with PD-L1 expression ≥ 50%. The occurrence of irAEs may be a surrogate of clinical activity and improved outcomes in this setting.
- Published
- 2020
9. Host immune-inflammatory markers to unravel the heterogeneous outcome and assessment of patients with PD-L1 ≥50% metastatic non-small cell lung cancer and poor performance status receiving first-line immunotherapy
- Author
-
Giuseppe L. Banna, Marcello Tiseo, Diego L. Cortinovis, Francesco Facchinetti, Joachim G. J. V. Aerts, Cinzia Baldessari, Raffaele Giusti, Emilio Bria, Francesco Grossi, Rossana Berardi, Alessandro Morabito, Annamaria Catino, Carlo Genova, Francesca Mazzoni, Alain Gelibter, Francesca Rastelli, Marianna Macerelli, Rita Chiari, Stefania Gori, Giovanni Mansueto, Fabrizio Citarella, Luca Cantini, Erika Rijavec, Federica Bertolini, Federico Cappuzzo, Alessandro De Toma, Alex Friedlaender, Giulio Metro, Maria Vittoria Pensieri, Giampiero Porzio, Corrado Ficorella, David J. Pinato, Alessio Cortellini, Alfredo Addeo, and Pulmonary Medicine
- Subjects
Pulmonary and Respiratory Medicine ,non‐small cell lung cancer ,Lung Neoplasms ,Brief Report ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,neutrophil‐to‐lymphocyte ratio (NLR) ,General Medicine ,Prognosis ,B7-H1 Antigen ,Oncology ,SDG 3 - Good Health and Well-being ,immunotherapy ,inflammation ,neutrophil-to-lymphocyte ratio (NLR) ,non-small cell lung cancer ,performance status ,Carcinoma, Non-Small-Cell Lung ,Humans ,RC254-282 ,Retrospective Studies - Abstract
Background Patients with programmed cell death‐ligand 1 (PD‐L1) ≥50% metastatic non‐small cell lung cancer (mNSCLC) and ECOG performance status (PS) of 2 treated with first‐line immunotherapy have heterogeneous clinical assessment and outcomes. Methods To explore the role of immune‐inflammatory surrogates by the validated lung immuno‐oncology prognostic score (LIPS) score, including the neutrophil‐to‐lymphocyte ratio (NLR) and the pretreatment use of steroids, alongside other prognostic variables. A retrospective analysis of 128 patients with PS2 and PD‐L1 ≥50% mNSCLC treated between April 2018 and September 2019 with first‐line pembrolizumab in a real‐world setting was performed. Results With a median follow‐up of 15.3 months, the 1‐year overall survival (OS) and median progression‐free survival (PFS) were 32.3% (95% CI: 30.9–33.9) and 3.3 months (95% CI: 1.8–4.7), respectively. The NLR, lactate dehydrogenase (LDH) and pretreatment steroids results were the only significant prognostic factors on the univariate analysis and independent prognostic factors by the multivariate analysis on both OS and PFS. The LIPS score, including the NLR and pretreatment steroids, identified 29 (23%) favourable‐risk patients, with 0 factors, 1‐year OS of 67.6% and median PFS of 8.2 months; 57 (45%) intermediate‐risk patients, with 1 factor, 1‐year OS 32.1% and median PFS 2.7 months; 42 (33%) poor‐risk patients, with both factors, 1‐year OS of 10.7% and median PFS of 1.2 months. Conclusions The assessment of pre‐existing imbalance of the host immune response by combined blood and clinical immune‐inflammatory markers may represent a way to unravel the heterogeneous outcome and assessment of patients with mNSCLC and poor PS in the immune‐oncology setting., LIPS‐based suggestions for the first‐line treatment of patients with mNSCLC with PD‐L1 ≥ 50% and ECOG PS 2. The LIPS consists of the following validated prognostic factors: use of pretreatment steroids, NLR ≥4. The OS curve refers to all patients according to the LIPS score and corresponds to Figure 1A. For further details, see Figure 1 legend.
- Published
- 2022
10. 239 Efficacy and toxicity of single agent immune checkpoint inhibitors among adults with cancer aged ≥80 years: a multicenter international cohort study
- Author
-
Alessio Cortellini, Douglas B. Johnson, Amin Nassar, Sebastiano Buti, Pamela Pizzutilo, Fei Ye, Shravanti Macherla, David J. Pinato, Asrar Alahmadi, Giuseppe Lamberti, Anwaar Saeed, Ella Daniels, Paolo A. Ascierto, Carolyn J Presley, Sarah Abou Alaiwi, Melissa Bersanelli, Maluki Radford, Foteini Kalofonou, Tamara A. Sussman, Akiva Diamond, Maria Giovanna Dal Bello, Christopher J. Hoimes, Paolo Marchetti, Domenico Mallardo, Weijie Ma, Rebecca Irlmeier, Teja Ganta, Raffaele Giusti, Andrea Botticelli, Neha Debnath, Caroline A. Nebhan, Carlo Genova, Toni K. Choueiri, Biagio Ricciuti, Abdul Rafeh Naqash, Nikhil H. Ramaiya, Annamaria Catino, Haocan Song, Vito Vanella, Marco Filetti, Yinghong Wang, Thomas U. Marron, Chiara Casartelli, Dwight H. Owen, and Domenico Galetta
- Subjects
Pharmacology ,Oncology ,Cancer Research ,medicine.medical_specialty ,business.industry ,Immune checkpoint inhibitors ,Immunology ,Cancer ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,medicine.disease ,Internal medicine ,Toxicity ,medicine ,Molecular Medicine ,Immunology and Allergy ,Single agent ,business ,RC254-282 ,Cohort study - Abstract
BackgroundImmune checkpoint inhibitors (ICIs) are approved by the U.S. Food&Drug Administration in over 17 tumor types. Older adult patients make up about a quarter of all cancer patients but are historically understudied in cancer clinical trials. ICIs are associated with immune-related adverse events (irAEs), which may be particularly morbid for older adult patients with underlying comorbidities and impaired functional status. In this study, we provide insight into the real-world safety and efficacy of ICIs among older adult patients (≥80 years) with cancer.MethodsThis is a multicenter, international retrospective study of tumor-agnostic older adult patients with cancer treated with single-agent ICIs between 2010–2019 from 18 academic centers in the U.S. and Europe. A cohort of 928 patients aged ≥80 years during treatment with ICI was assembled and analyzed to evaluate clinical outcomes and irAE patterns in older adult patients treated with single-agent ICIs.ResultsMedian age at ICI initiation was 83.0 years (range 75.8–97.0). Most patients (86.9%) were treated with anti-PD-1 therapy. Among the full cohort, the three most common tumors were non-small cell lung cancer (NSCLC, 37.2%,n=345), melanoma (35.5%,n=329), and genitourinary (GU) tumors (16.5%,n=153). Objective response rates for patients with NSCLC, melanoma, and GU tumors were 32.2%, 39.3%, and 26.2%, respectively. Median progression-free survival (PFS) was 6.7 months (95%CI, 5.2–8.6) for patients with NSCLC, 11.1 months (95%CI, 8.9–16.0) for patients with melanoma, and 6.0 months (95% CI, 5.0–10.7) for patients with GU malignancy. Median overall survival (OS) was 10.9 months (95%CI, 8.6–13.1) for patients with NSCLC, 30.0 months (95%CI, 23.6–46.4) for patients with melanoma, and 15.0 months (95%CI 9.1–25.4) for GU patients (Figure 1A-C). Within histology-specific cohorts (NSCLC, melanoma and GU), clinical outcomes were similar across age subgroups (90). Among all patients (N=928), 41.3% experienced ≥1 irAE(s), including 12.2% reported to be grade (G)3–4. No irAE-related deaths occurred. The median time to irAE onset was 9.8 weeks; 57% occurred within the first 3 months after ICI initiation. ICI was discontinued due to irAEs in 16.1% patients. There was no significant difference in the rate of irAEs among patients age ConclusionsICIs are effective and generally well-tolerated among older patients with cancer. However, ICI discontinuation due to irAE is more frequent with increasing age.
- Published
- 2021
11. INfluenza Vaccine Indication during therapy with Immune checkpoint inhibitors: A multicenter prospective observational study (INVIDIa-2)
- Author
-
Diana Giannarelli, Sandro Pignata, Vincenzo Montesarchio, Massimo Di Maio, Melissa Bersanelli, Sebastiano Buti, Raffaele Giusti, Marcello Tiseo, Marco Filetti, Corrado Ficorella, Elena Verzoni, Ugo De Giorgi, Carmine Pinto, Ernesto Rossi, Evaristo Maiello, Maria R Migliorino, Annamaria Catino, Francesca Mazzoni, Francesco Grossi, Giorgia Guaitoli, Marco Maruzzo, Giuseppe Aprile, Marilena Di Napoli, Giorgia Negrini, Antonio Russo, Saverio Cinieri, Mimma Rizzo, Fable Zustovich, Vieri Scotti, Alberto Clemente, Paola Ermacora, Pamela Francesca Guglielmini, Antonello Veccia, Chiara Casadei, Francesco Verderame, Lucia Fratino, Caterina Accettura, Manlio Mencoboni, Cinzia Baldessari, Andrea Camerini, Letizia Laera, Mariella Sorarù, Paolo Andrea Zucali, Valentina Guadalupi, Francesco Leonardi, Michele Tognetto, Francesco Di Costanzo, Francesco di Costanzo, Roberto Labianca, Luigi Bernardi, Bersanelli M., Giannarelli D., De Giorgi U., Pignata S., Di Maio M., Clemente A., Verzoni E., Giusti R., Di Napoli M., Aprile G., Ermacora P., Catino A., Scotti V., Mazzoni F., Guglielmini P.F., Veccia A., Maruzzo M., Rossi E., Grossi F., Casadei C., Ficorella C., Montesarchio V., Verderame F., Rizzo M., Guaitoli G., Fratino L., Accettura C., Mencoboni M., Zustovich F., Baldessari C., Cinieri S., Camerini A., Laera L., Soraru M., Zucali P.A., Guadalupi V., Leonardi F., Tiseo M., Tognetto M., Di Costanzo F., Pinto C., Negrini G., Russo A., Migliorino M.R., Filetti M., and Buti S.
- Subjects
Male ,Cancer Research ,Time Factors ,immunogenicity ,0302 clinical medicine ,Risk Factors ,Neoplasms ,vaccine ,Clinical endpoint ,Immunology and Allergy ,antibodies ,immunization ,immunotherapy ,neoplasm ,vaccination ,Prospective Studies ,030212 general & internal medicine ,Immune Checkpoint Inhibitors ,RC254-282 ,Clinical/Translational Cancer Immunotherapy ,Aged, 80 and over ,Incidence ,Incidence (epidemiology) ,virus diseases ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Middle Aged ,Vaccination ,Treatment Outcome ,Italy ,Oncology ,Influenza Vaccines ,030220 oncology & carcinogenesis ,Molecular Medicine ,Female ,Adult ,medicine.medical_specialty ,Influenza vaccine ,Immunology ,Vaccine Efficacy ,Risk Assessment ,Young Adult ,03 medical and health sciences ,Internal medicine ,Influenza, Human ,medicine ,Humans ,Lung cancer ,Adverse effect ,Aged ,Pharmacology ,business.industry ,Cancer ,medicine.disease ,Immunization ,business - Abstract
BackgroundUntil now, no robust data supported the efficacy, safety and recommendation for influenza vaccination in patients with cancer receiving immune checkpoint inhibitors (ICIs).MethodsThe prospective multicenter observational INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors (INVIDIa-2) study investigated the clinical effectiveness of influenza vaccination in patients with advanced cancer receiving ICIs, enrolled in 82 Italian centers from October 2019 to January 2020. The primary endpoint was the time-adjusted incidence of influenza-like illness (ILI) until April 30, 2020. Secondary endpoints regarded ILI severity and vaccine safety.ResultsThe study enrolled 1279 patients; 1188 patients were evaluable for the primary endpoint analysis. Of them, 48.9% (581) received influenza vaccination. The overall ILI incidence was 8.2% (98 patients). Vaccinated patients were significantly more frequently elderly (pvs 29.8%, p=0.027). ILI lethality was, respectively, 0% in vaccinated and 4.3% in unvaccinated patients. Vaccine-related adverse events were rare and mild (1.5%, grades 1–2).ConclusionThe INVIDIa-2 study results support a positive recommendation for influenza vaccination in patients with advanced cancer receiving immunotherapy.
- Published
- 2021
12. Gender Differences and Immunotherapy Outcome in Advanced Lung Cancer
- Author
-
Vito Longo, Annamaria Catino, Tiziana Vavalà, Domenico Galetta, and Pamela Pizzutilo
- Subjects
Oncology ,medicine.medical_specialty ,Lung Neoplasms ,QH301-705.5 ,medicine.medical_treatment ,Review ,Catalysis ,Inorganic Chemistry ,Immune system ,Sex Factors ,Internal medicine ,medicine ,Animals ,Humans ,Physical and Theoretical Chemistry ,Risk factor ,Biology (General) ,Lung cancer ,Molecular Biology ,QD1-999 ,Spectroscopy ,business.industry ,Organic Chemistry ,Healthy subjects ,Cancer ,General Medicine ,Immunotherapy ,medicine.disease ,Prognosis ,Computer Science Applications ,Chemistry ,lung cancer ,gender differences ,Cancer evolution ,business ,Developed country - Abstract
In developed countries, lung cancer is the leading cause of cancer-related death in both sexes. Although cigarette smoking represents the principal risk factor for lung cancer in females, the higher proportion of this neoplasm among non-smoking women as compared with non-smoking men implies distinctive biological aspects between the two sexes. Gender differences depend not only on genetic, environmental, and hormonal factors but also on the immune system, and all these aspects are closely interconnected. In the last few years, it has been confirmed that the immune system plays a fundamental role in cancer evolution and response to oncological treatments, specifically immunotherapy, with documented distinctions between men and women. Consequently, in order to correctly assess cancer responses and disease control, considering only age and reproductive status, the results of studies conducted in female patients would probably not categorically apply to male patients and vice versa. The aim of this article is to review recent data about gender disparities in both healthy subjects’ immune system and lung cancer patients; furthermore, studies concerning gender differences in response to lung cancer immunotherapy are examined.
- Published
- 2021
13. 125P Radiomic signature from baseline CT Scan to predict initial response to treatment in advanced/unresectable pleural mesothelioma: Preliminary data
- Author
-
A. Catino, A. Fanizzi, P.P.S. Perrotti, P. Pizzutilo, M. Montrone, D. Galetta, and R. Massafra
- Subjects
Oncology ,Hematology - Published
- 2022
14. Nivolumab in never-smokers with advanced squamous non-small cell lung cancer: Results from the Italian cohort of an expanded access program
- Author
-
Marina Chiara Garassino, Annamaria Catino, Luana Calabrò, Francesca Ambrosio, Carmelo Bengala, Alessandro Follador, Fabiana Vitiello, Floriana Morgillo, Lucio Crinò, Paola Bordi, Enrico Mini, Giuseppe Lo Russo, Enrico Vasile, Andrea Ardizzoni, Antonio Santo, Federico Cappuzzo, Alessandro Scoppola, Giuseppe Altavilla, Diana Giannarelli, Enrico Cortesi, Natale Tedde, Fausto Barbieri, Garassino, M. C., Crino, L., Catino, A., Ardizzoni, A., Cortesi, E., Cappuzzo, F., Bordi, P., Calabro, L., Barbieri, F., Santo, A., Altavilla, G., Ambrosio, F., Mini, E., Vasile, E., Morgillo, F., Scoppola, A., Bengala, C., Follador, A., Tedde, N., Giannarelli, D., Lo Russo, G., Vitiello, F., Garassino, Marina Chiara, Crinò, Lucio, Catino, Annamaria, Ardizzoni, Andrea, Cortesi, Enrico, Cappuzzo, Federico, Bordi, Paola, Calabrò, Luana, Barbieri, Fausto, Santo, Antonio, Altavilla, Giuseppe, Ambrosio, Francesca, Mini, Enrico, Vasile, Enrico, Morgillo, Floriana, Scoppola, Alessandro, Bengala, Carmelo, Follador, Alessandro, Tedde, Natale, Giannarelli, Diana, Lo Russo, Giuseppe, and Vitiello, Fabiana
- Subjects
Oncology ,Male ,Cancer Research ,Lung Neoplasms ,medicine.medical_treatment ,never-smokers ,carcinoma ,Health Services Accessibility ,Cohort Studies ,0302 clinical medicine ,Carcinoma, Non-Small-Cell Lung ,80 and over ,Medicine ,030212 general & internal medicine ,squamous non-small cell lung cancer ,RC254-282 ,Aged, 80 and over ,never-smoker ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,General Medicine ,Middle Aged ,Prognosis ,expanded access program ,italian ,nivolumab ,Survival Rate ,Nivolumab ,030220 oncology & carcinogenesis ,Cohort ,Carcinoma, Squamous Cell ,Disease Progression ,Female ,Case-Control Studie ,Human ,Cohort study ,Expanded access program, italian, never-smokers, nivolumab, squamous non-small cell lung cancer, adult, aged, aged, 80 and over, carcinoma, non-small-cell lung, squamous cell, case-control studies, cohort studies, disease progression, female, follow-up studies, humans, lung neoplasms, male, middle aged, nivolumab, non-smokers, Prognosis, survival rate, health services accessibility ,Adult ,medicine.medical_specialty ,Italian ,Prognosi ,Follow-Up Studie ,03 medical and health sciences ,Internal medicine ,Humans ,Survival rate ,Aged ,squamous cell ,Expanded access program ,business.industry ,Case-control study ,Immunotherapy ,Non-Smokers ,Lung Neoplasm ,non-small-cell lung ,Non-Smoker ,Expanded access ,Case-Control Studies ,Squamous non-small cell lung cancer ,Cohort Studie ,business ,Follow-Up Studies - Abstract
Objectives: Never-smokers may be a distinct subgroup among patients with advanced non-small cell lung cancer, appearing to benefit less from immunotherapy than smokers. We report results from never-smokers enrolled in the Italian cohort of the nivolumab expanded access program in pre-treated patients with advanced squamous non-small cell lung cancer. Materials and methods: Nivolumab (3 mg/kg every 2 weeks for ≤24 months) was available on physician request. Efficacy data included objective tumor response, date of progression, and survival information. Safety was monitored. Results: Overall, 371 patients received at least one dose of nivolumab, including 31 never-smokers (8%). Objective response rate, disease-control rate, and median overall survival were 23%, 45%, and 12.1 months (95% confidence interval: 3.7–20.4), respectively, in never-smokers, and 18%, 47%, and 7.9 months (95% confidence interval: 6.2–9.6), respectively, in the overall expanded access program population. Any-grade and grade 3–4 treatment-related adverse events were reported in 12 (39%) and 3 (10%) never-smokers, respectively, and in 109 (29%) and 21 (6%) patients, respectively, in the overall expanded access program population. Grade 3–4 treatment-related adverse events in non-smokers were increased transaminases (n = 2; 6%) and diarrhea (n = 1; 3%). Treatment-related adverse events led to treatment discontinuation in 4 non-smokers (17%) and in 26 patients (9%) overall. Conclusion: Pre-treated never-smokers with advanced squamous non-small cell lung cancer in this Italian expanded access program demonstrated efficacy and safety that were consistent with those in the overall expanded access program population and clinical trials. These results suggest that a proportion of never-smoker patients with squamous non-small cell lung cancer may be responsive to immunotherapy. Other factors, such as the tumor mutational load and the status of programmed death-ligand 1, anaplastic lymphoma kinase, and epidermal growth factor receptor, might play a potential key role.
- Published
- 2018
15. Cytokines Are at the Heart of It
- Author
-
Anna Catino
- Subjects
lcsh:Diseases of the circulatory (Cardiovascular) system ,Cardiotoxicity ,business.industry ,cardiotoxicity ,leukemia ,heart failure ,cytokine release syndrome ,lymphoma ,chimeric antigen receptor T cell therapy ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,medicine.disease ,lcsh:RC254-282 ,Lymphoma ,Cytokine release syndrome ,Leukemia ,Oncology ,lcsh:RC666-701 ,Heart failure ,Cancer research ,Medicine ,Chimeric Antigen Receptor T-Cell Therapy ,Car t cells ,Cardiology and Cardiovascular Medicine ,business - Published
- 2020
16. Tobacco control in Europe: A review of campaign strategies for teenagers and adults
- Author
-
V. Lapadula, Domenico Galetta, Alessandra Di Lauro, D. Ricci, Pamela Pizzutilo, V. Lamorgese, D. Bafunno, Annamaria Catino, A. Mastrandrea, and P. Petrillo
- Subjects
Adult ,0301 basic medicine ,Adolescent ,medicine.medical_treatment ,media_common.quotation_subject ,Smoking Prevention ,03 medical and health sciences ,0302 clinical medicine ,Intervention (counseling) ,Environmental health ,Tobacco ,medicine ,Humans ,Quality (business) ,Mass Media ,Excise ,media_common ,Mass media ,business.industry ,Tobacco control ,Hematology ,Europe ,030104 developmental biology ,Systematic review ,Oncology ,030220 oncology & carcinogenesis ,Health Resources ,Smoking cessation ,business ,Inclusion (education) - Abstract
Background In Europe the prevalence of tobacco use in adults and adolescents is among the highest within the WHO regions. Many resources have been allocated toward the prevention and support for smoking cessation. However, the implemented strategies in Europe have not been systematically evaluated. Methods A systematic literature review was carried out to identify studies that analyzed the efficacy of the main smoking-prevention campaigns conducted in Europe. PRISMA guidelines were used to systematically review and extract data. Results A total of 24 studies meeting inclusion criteria were identified. Each article was thoroughly reviewed and evaluated for quality, design, and methodology, with reference to the main areas of intervention: school (8); mass media (4) and technological tools (4); smoke-free environments (3); packaging (2) and taxes (3). The school programmes focusing on building skills to recognize and resist negative influences, the intensive use of media and technological equipments, health warnings and excise taxes have showed to be effective tools in reducing the tobacco use. Conclusions Intervention programmes to implement tobacco control policies and smoking cessation are active in many European countries. However, these programmes need to be constantly sustained to achieve a long term efficacy.
- Published
- 2019
17. Discordance between FISH, IHC, and NGS Analysis of ALK Status in Advanced Non–Small Cell Lung Cancer (NSCLC): a Brief Report of 7 Cases
- Author
-
Stefania Tommasi, Rosanna Lacalamita, Anna Scattone, Domenico Galetta, Laura Schirosi, Lucia Caldarola, Francesco Alfredo Zito, Elisabetta Sara Montagna, Anita Mangia, Annamaria Catino, and Gabriella Serio
- Subjects
0301 basic medicine ,Cancer Research ,medicine.medical_treatment ,non-small cell lung cancer (NSCLC) ,lcsh:RC254-282 ,Targeted therapy ,03 medical and health sciences ,0302 clinical medicine ,hemic and lymphatic diseases ,Gene duplication ,medicine ,Anaplastic lymphoma kinase ,Polysomy ,medicine.diagnostic_test ,Crizotinib ,business.industry ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,medicine.disease ,030104 developmental biology ,Oncology ,030220 oncology & carcinogenesis ,Cancer research ,Immunohistochemistry ,business ,Fluorescence in situ hybridization ,medicine.drug - Abstract
BACKGROUND: Anaplastic lymphoma kinase (ALK) rearrangement represents a landmark in the targeted therapy of non–small cell lung cancer (NSCLC). Immunohistochemistry (IHC) is a sensitive and specific method to detect ALK protein expression, possibly an alternative to fluorescence in situ hybridization (FISH). In this study, the concordance of FISH and IHC to determine ALK status was evaluated, particularly focusing on discordant cases. MATERIALS AND METHODS: ALK status was tested by FISH and the IHC validated method (Ventana ALK (D5F3) CDx Assay) in 95 NSCLCs. Discordant cases were analyzed also by next-generation sequencing (NGS). The response to crizotinib of treated patients was recorded. RESULTS: Seven (7.3%) discordant cases were ALK FISH positive and IHC negative. They showed coexistent split signals pattern, with mean percentage of 15.4%, and 5′ deletions pattern, with mean percentage 31.7%. Two cases had also gene amplification pattern. In three cases (42.8 %), the polysomy was observed. The NGS assay confirmed IHC results. In these patients, the treatment with crizotinib was ineffective. CONCLUSIONS: In our discordant cases, a coexistent complex pattern (deleted, split, and amplified/polysomic) of ALK gene was observed by FISH analysis. These complex rearranged cases were not detectable by IHC, and it could be speculated that more complex biological mechanisms could modulate protein expression. These data highlight the role of IHC and underscore the complexity of the genetic pattern of ALK. It could be crucial to consider these findings in order to best select patients for anti-ALK treatment in daily clinical practice.
- Published
- 2019
18. Incidence of Infections and Predictors of Mortality During Checkpoint Inhibitor Immunotherapy in Patients With Advanced Lung Cancer: A Retrospective Cohort Study
- Author
-
Pamela Pizzutilo, Francesco Di Gennaro, Sandro Cassiano, Davide Fiore Bavaro, Annalisa Saracino, V. Lamorgese, F. Pesola, Fabio Signorile, Laura Monno, Ilaria Marech, Annamaria Catino, Gioacchino Angarano, and Domenico Galetta
- Subjects
medicine.medical_specialty ,Urinary system ,Pembrolizumab ,Major Articles ,infectious diseases consultation ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Risk of mortality ,Medicine ,pneumonia ,030212 general & internal medicine ,Lung cancer ,business.industry ,Incidence (epidemiology) ,Retrospective cohort study ,medicine.disease ,Pneumonia ,Infectious Diseases ,AcademicSubjects/MED00290 ,Oncology ,bacterial infections ,immunocompromised hosts ,030220 oncology & carcinogenesis ,advanced lung cancer ,Nivolumab ,business - Abstract
Background Immune checkpoint inhibitors (ICIs) have revolutionized nonsmall cell lung cancer (NSCLC) treatment and significantly increased overall survival of patients. However, the incidence of concurrent infections and their management is still debated. Methods From August 2015 to October 2019, all consecutive patients with NSCLC who received nivolumab or pembrolizumab as first- or second-line therapy were retrospectively evaluated. At the time of analysis all patients had died. Clinical characteristics of patients, type of infections, and predictors of mortality were analyzed. Results A total of 118 patients were identified: 74 in the nivolumab group and 44 in the pembrolizumab group. At least 1 infection was recorded in 22% of the nivolumab-group versus 27% of the pembrolizumab-group (P = .178). In both groups, the main infection was pneumonia, followed by skin and soft tissue infections, urinary tract infections, and gastroenteritis. Crude mortality for first infection was 10.7%, followed by 25% and 40% for the second and third recurrence, respectively (p for trend = .146). No opportunistic infections were recorded. It is notable that, by Cox-regression model, the independent predictor of mortality was a higher Eastern Cooperative Oncology Group performance status at baseline (P, Immune checkpoint inhibitors have revolutionized non–small cell lung cancer treatment. In these patients, multidisciplinary management of concurrent infections with Infectious Diseases specialists may reduce the risk of mortality. Further studies to investigate risk factors for infections are warranted.
- Published
- 2021
19. Favourable outcome of coronavirus disease 2019 in a patient with anaplastic lymphoma kinase-positive non-small-cell lung cancer receiving alectinib
- Author
-
Michele Montrone, Annamaria Catino, Vito Longo, Vincenzo Palmieri, and Domenico Galetta
- Subjects
Oncology ,Alectinib ,medicine.medical_specialty ,2019-20 coronavirus outbreak ,Cancer Research ,Coronavirus disease 2019 (COVID-19) ,business.industry ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,medicine.disease ,Tomography x ray computed ,Internal medicine ,medicine ,Non small cell ,business ,Lung cancer ,Anaplastic Lymphoma Kinase Positive - Published
- 2020
- Full Text
- View/download PDF
20. ROC Analysis Identifies Baseline and Dynamic NLR and dNLR Cut-Offs to Predict ICI Outcome in 402 Advanced NSCLC Patients
- Author
-
F. Arizio, Pamela Pizzutilo, Annapaola Mariniello, Michele Montrone, Domenico Galetta, Giuseppe Migliaretti, Silvia Genestroni, Fabrizio Tabbò, A. Alemanni, Hector Soto Parra, Gloria Borra, Tiziana Vavalà, Roberta Buosi, Simona Carnio, Alice Lunghi, Silvia Novello, Annamaria Catino, Ilaria Stura, and Gianmauro Numico
- Subjects
0301 basic medicine ,Oncology ,medicine.medical_specialty ,NSCLC ,immunotherapy ,biomarkers ,NLR ,dNLR ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Overall survival ,Medicine ,Progression-free survival ,Receiver operating characteristic ,business.industry ,Proportional hazards model ,fungi ,Retrospective cohort study ,Peripheral blood ,030104 developmental biology ,030220 oncology & carcinogenesis ,Non small cell ,business ,Stage iv - Abstract
Background: Neutrophil-to-Lymphocyte Ratio (NLR) and derived Neutrophils-to-(Leukocytes minus neutrophils) Ratio (dNLR) have been proposed as possible biomarkers of response to immune checkpoint inhibitors (ICI). However, in non-small cell lung cancer (NSCLC) studies, various NLR and/or dNLR cut-offs have been used, manly based on previous reports on melanoma. Methods: In this Italian multicenter retrospective study, NLR, dNLR, platelet-to-lymphocyte ratio, albumin, and lactate dehydrogenase (LDH) were longitudinally assessed in patients with stage IV non-small cell lung cancer (NSCLC) treated with ICI. The primary objective was to evaluate if baseline parameters predicted response to ICI, using Receiver Operating Characteristic (ROC) curves. Secondary endpoint was to evaluate if dynamic changing of NLR and dNLR also predicted response. Results: Data of 402 patients were collected and analyzed. Among the baseline parameters considered, NLR and dNLR were the most appropriate biomarkers according to the ROC analyses, which also identified meaningful cut-offs (NLR = 2.46, dNLR = 1.61). Patients with low ratios reported a significantly improved outcome, in terms of overall survival (p = 0.0003 for NLR, p = 0.0002 for dNLR) and progression free survival (p = 0.0004 for NLR, p = 0.005 for dNLR). The role of NLR and dNLR as independent biomarkers of response was confirmed in the Cox regression model. When assessing NLR and dNLR dynamics from baseline to cycle 3, a decrease &ge, 1.04 for NLR and &ge, 0.41 for dNLR also predicted response. Conclusions in our cohort, we confirmed that NLR and dNLR, easily assessable on peripheral blood, can predict response at baseline and early after ICI initiation. For both baseline and dynamic assessment, we identified clinically meaningful cut-offs, using ROC curves.
- Published
- 2020
- Full Text
- View/download PDF
21. LBA82 Influenza-like illness and SARS-Cov-2 in the multicenter, prospective, observational INVIDIa-2 study (INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: A transversal challenge): A FICOG study
- Author
-
P. Bonomo, Annamaria Catino, Giorgia Guaitoli, Francesca Mazzoni, Elena Verzoni, Melissa Bersanelli, Paola Ermacora, Emanuela Rossi, Diana Giannarelli, Lorenzo Calvetti, U. De Giorgi, Marco Filetti, Federica Grosso, Marco Maruzzo, G. Procopio, Alberto Clemente, Sebastiano Buti, Francesco Grossi, Antonello Veccia, and M. Di Napoli
- Subjects
medicine.medical_specialty ,Influenza-like illness ,Influenza vaccine ,business.industry ,Incidence (epidemiology) ,virus diseases ,Hematology ,medicine.disease ,Article ,respiratory tract diseases ,Clinical trial ,Vaccination ,Oncology ,Internal medicine ,medicine ,Clinical endpoint ,Population study ,Lung cancer ,business - Abstract
Background: The susceptibility of advanced cancer patients treated with immune checkpoint inhibitors (ICI) for viral infections has not been investigated Currently, there are no robust data supporting the efficacy, safety and recommendation for influenza vaccination in cancer patients receiving ICI Methods: The prospective, multicenter, observational INVIDIa-2 study investigated the clinical efficacy of influenza vaccination in advanced cancer patients with solid tumors receiving ICI between October 2019 and January 2020 The incidence of influenza-like illness (ILI, primary endpoint) was observed until April 30, 2020 Secondary endpoints included a non-prespecified analysis for COVID-19 Results: The study enrolled 1279 patients;1188 were evaluable Of them, 11 patients developed ILI symptoms with confirmed diagnosis of COVID-19 (incidence of 0 9% and lethality of 72%, irrespective of the flu vaccination) Of the remaining 1177 patients, 574 received flu vaccination (48 8%) The ILI incidence was 7 7% (91 patients of 1177) Patients receiving the flu vaccine were significantly more frequently elderly (p
- Published
- 2020
- Full Text
- View/download PDF
22. Clinicopathologic correlates of pembrolizumab efficacy in patients with advanced NSCLC and a PD-L1 expression of ≥ 50%
- Author
-
Alfredo Addeo, Vincenzo Di Noia, Robert A. Belderbos, Francesco Grossi, Joachim G.J.V. Aerts, Giampiero Porzio, Simona Scodes, Raffaele Giusti, Federico Cappuzzo, Giorgia Guaitoli, Diego Signorelli, Lorenzo Antonuzzo, Corrado Ficorella, Alessio Cortellini, Luigi Della Gravara, Alex Friedlaender, Giovanni Mansueto, Sebastiano Buti, Marcello Tiseo, Emilio Bria, Paolo Marchetti, Simona Carnio, Domenico Galetta, Alain Gelibter, Giada Targato, Ornella Cantale, Lorenza Landi, Diego Cortinovis, Maria Giovanna Dal Bello, Alessandro De Toma, Olga Nigro, Russano Marco, Luca Sala, Cinzia Baldessari, Michele De Tursi, Paola Bordi, Mariangela Torniai, Miriam Grazia Ferrara, Vincenzo Sforza, Marco Filetti, Maria Rita Migliorino, Claudia Proto, Giuseppe Luigi Banna, Alessandro Tuzi, Giulio Metro, Daniele Santini, Ettore D'Argento, Erika Rijavec, Stefania Gori, Biagio Ricciuti, Serena Ricciardi, Annamaria Catino, Rossana Berardi, Federica Zoratto, Marianna Macerelli, Paolo Bironzo, Luca Cantini, Fausto Barbieri, Francesca Mazzoni, Rita Chiari, Francesca Rastelli, Alessio Grieco, Alessandro Morabito, Fabrizio Citarella, Matteo Santoni, Carlo Genova, Danilo Rocco, Francesco Passiglia, Marianna Tudini, and Pamela Pizzutilo
- Subjects
Oncology ,medicine.medical_specialty ,business.industry ,First line ,Pembrolizumab ,medicine.disease ,Metastasis ,Clinical trial ,Multicenter study ,Internal medicine ,Tobacco exposure ,medicine ,In patient ,Pd l1 expression ,business - Abstract
BackgroundSingle agent pembrolizumab represents the standard first line option for metastatic non-small-cell-lung-cancer (NSCLC) patients with a PD-L1 (programmed death-ligand 1) expression of ≥ 50%.MethodsWe conducted a multicenter study aimed at evaluating the clinicopathologic correlates of pembrolizumab efficacy in patients with treatment-naïve NSCLC and a PD-L1 TPS ≥ 50%.Results1026 consecutive patients were included. ECOG-PS ≥ 2 (p < 0.0001) and bone metastases (p = 0.0003) were confirmed to be independent predictors of a worse ORR. Former smokers (p = 0.0002), but not current smokers (p = 0.0532) were confirmed to have a significantly prolonged PFS compared to never smokers at multivariate analysis. ECOG-PS (p < 0.0001), bone metastases (p < 0.0001) and liver metastases (p < 0.0001) were also confirmed to be independent predictors of a worse PFS. Previous palliative RT was significantly related to a shortened OS (p = 0.0104), while previous non-palliative RT was significantly related to a prolonged OS (p = 0.0033). Former smokers (p = 0.0131), but not current smokers (p = 0.3433) were confirmed to have a significantly prolonged OS compared to never smokers. ECOG-PS (p < 0.0001), bone metastases (p < 0.0001) and liver metastases (p < 0.0001) were also confirmed to be independent predictors of a shortened OS. A PD-L1 expression of ≥ 90%, as assessed by recursive partitioning, was associated with significantly higher ORR (p = 0.0204), and longer and OS (p = 0.0346) at multivariable analysis.Conclusionspembrolizumab was effective in a large cohort of NSCLC patients treated outside of clinical trials. We confirmed that the absence of tobacco exposure, and the presence of bone and liver metastasis are associated with worse clinical outcomes to pembrolizumab. Increasing levels of PD-L1 expression may help identifying a subset of patients who derive a greater benefit from pembrolizumab monotherapy.
- Published
- 2020
23. Esophageal Stricture Caused by ALK-Positive NSCLC Esophageal Metastasis Resolved After a Few Days of Lorlatinib Therapy Without Stent Placement
- Author
-
Rosanna Lacalamita, Domenico Galetta, Gabriella Del Bene, Ippazio Ugenti, F. Pesola, Michele Montrone, Annamaria Catino, Pamela Pizzutilo, Ilaria Marech, and Vito Longo
- Subjects
Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,business.industry ,ALK-Positive ,Case Report ,medicine.disease ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Lorlatinib ,lcsh:RC254-282 ,Stent placement ,Oncology ,Esophageal Metastasis ,Esophageal stricture ,medicine ,Radiology ,business - Published
- 2020
24. DiM: Prognostic Score for Second- or Further-line Immunotherapy in Advanced Non–Small-Cell Lung Cancer: An External Validation
- Author
-
Benedetta Trevisan, Domenico Galetta, Filippo Pagani, Diego Signorelli, Niccolò Varesano, Giovanni Randon, Massimo Di Maio, Pamela Pizzutilo, Claudia Proto, Roberto Ferrara, Giulia Galli, Arsela Prelaj, Vito Longo, Michele Montrone, Annamaria Catino, Gabriella Del Bene, Giuseppe Lo Russo, Monica Ganzinelli, Nicoletta Zilembo, Marina Chiara Garassino, Alessandro De Toma, F. Pesola, and Valter Torri
- Subjects
0301 basic medicine ,Pulmonary and Respiratory Medicine ,Oncology ,Adult ,Male ,Cancer Research ,medicine.medical_specialty ,Lung Neoplasms ,medicine.medical_treatment ,Adenocarcinoma of Lung ,Second-line ,NSCLC ,Systemic therapy ,Prognostic score ,Predictive score ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Carcinoma, Non-Small-Cell Lung ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Stage (cooking) ,Lung cancer ,Biomarker ,Immunotherapy ,Aged ,Retrospective Studies ,Aged, 80 and over ,Chemotherapy ,business.industry ,External validation ,Middle Aged ,medicine.disease ,Prognosis ,Survival Rate ,030104 developmental biology ,030220 oncology & carcinogenesis ,Carcinoma, Squamous Cell ,Biomarker (medicine) ,Female ,business ,Follow-Up Studies - Abstract
Other than the programmed cell death ligand 1 (PD-L1) value, oncologists have only the clinical characteristics of patients with advanced non-small-cell lung cancer (aNSCLC) to determine candidates for immunotherapy. A clinical prognostic score composed of the Eastern Cooperative Oncology Group performance status, sex, histologic type, stage, platinum-based first-line therapy, and response to first-line therapy has categorized 3 prognostic groups for patients undergoing second-line chemotherapy. We sought to validate the same score for patients with aNSCLC treated with second- or further-line immunotherapy.We collected data from 2 Italian centers. A score was generated to divide patients into 3 prognostic groups: best, score 5; intermediate, score 5 to 9; and worst, score9. Overall survival (OS) and progression-free survival (PFS) were the endpoints.A total of 347 patients were included for analysis. Their median age was 66 years (range, 30-88 years), most were aged 70 years (67.5%), 70.7% were men, 79.5% were smokers, and 74.6% had had adenocarcinoma. The Eastern Cooperative Oncology Group performance status was 0 for 23%, 1 for 54.5%, and 2 for 22.5%. Of the 347 patients, 28% were in the best prognosis, 51% in the intermediate, and 21% in the worst prognosis group, respectively. The median OS was 18.0 months for the best, 8.5 months for the intermediate (hazard ratio [HR] vs. best, 1.83; 95% confidence interval [CI], 1.35-2.47; P .001) and 2.6 months for worst (HR vs. best, 5.77; 95% CI, 3.99-8.33; P .001) group. The median PFS was 3.4 months for the best, 3.7 months for the intermediate (HR vs. best, 1.35; 95% CI, 1.03-1.77; P = .032), and 1.9 months for the worst (HR vs. best, 2.51; 95% CI, 1.80-3.50; P .001) group.The prognostic score was able to predict the outcomes of patients with aNSCLC who had received immunotherapy. The worst category showed a dismal life expectancy and probably would not benefit from active systemic therapy. Thus, for these patients, best supportive care could be the best choice.
- Published
- 2020
25. Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50%
- Author
-
Giovanni Mansueto, Lorenza Landi, Francesco Grossi, Cinzia Baldessari, Michele De Tursi, Alessio Cortellini, Vincenzo Sforza, Alain Gelibter, Raffaele Giusti, Biagio Ricciuti, Giuseppe Luigi Banna, Daniele Santini, Giorgia Guaitoli, Joachim G.J.V. Aerts, Russano Marco, Rita Chiari, Ornella Cantale, Luca Sala, Mariangela Torniai, Stefania Gori, Claudia Proto, Luigi Della Gravara, Diego Signorelli, Lorenzo Antonuzzo, Emilio Bria, Francesco Passiglia, Serena Ricciardi, Luca Cantini, Corrado Ficorella, Simona Carnio, Annamaria Catino, Paola Bordi, Vincenzo Di Noia, Miriam Grazia Ferrara, Maria Giovanna Dal Bello, Domenico Galetta, Sebastiano Buti, Federica Zoratto, Giampiero Porzio, Marianna Tudini, Paolo Marchetti, Diego Cortinovis, Erika Rijavec, Matteo Santoni, Carlo Genova, Danilo Rocco, Alex Friedlaender, Robert A. Belderbos, Ettore D'Argento, Simona Scodes, Pamela Pizzutilo, Marcello Tiseo, Alfredo Addeo, Marianna Macerelli, Rossana Berardi, Giada Targato, Federico Cappuzzo, Francesca Mazzoni, Alessandro Morabito, Fabrizio Citarella, Maria Rita Migliorino, Alessandro De Toma, Olga Nigro, Paolo Bironzo, Fausto Barbieri, Marco Filetti, Alessandro Tuzi, Giulio Metro, Francesca Rastelli, Alessio Grieco, and Pulmonary Medicine
- Subjects
Oncology ,Cancer Research ,medicine.medical_treatment ,Bone metastases ,Liver metastases ,PD-L1 ,Performance status ,Radiotherapy ,Smoking status ,Pembrolizumab ,carcinoma ,Metastasis ,Antineoplastic Agents, Immunological ,bone metastases ,Carcinoma, Non-Small-Cell Lung ,middle aged ,antineoplastic agents ,Immunology and Allergy ,antibodies ,humans ,humanized ,adult ,liver metastases ,pd-l1 ,performance status ,radiotherapy ,smoking status ,aged ,antibodies, monoclonal ,immunological ,b7-h1 antigen ,non-small-cell lung ,female ,lung neoplasms ,male ,progression-free survival ,retrospective studies ,Adult ,Aged ,Antibodies ,Monoclonal ,Humanized ,Antineoplastic Agents ,Immunological ,B7-H1 Antigen ,Carcinoma ,Non-Small-Cell Lung ,Female ,Humans ,Lung Neoplasms ,Male ,Middle Aged ,Progression-Free Survival ,Retrospective Studies ,medicine.medical_specialty ,Immunology ,monoclonal ,Antibodies, Monoclonal, Humanized ,Internal medicine ,medicine ,Progression-free survival ,Lung cancer ,business.industry ,Retrospective cohort study ,medicine.disease ,Radiation therapy ,business - Abstract
Single-agent pembrolizumab represents the standard first-line option for metastatic non-small-cell lung cancer (NSCLC) patients with a PD-L1 (programmed death-ligand 1) expression of ≥ 50%. We conducted a multicenter retrospective study aimed at evaluating the clinicopathologic correlates of pembrolizumab effectiveness in patients with treatment-naive NSCLC and a PD-L1 expression of ≥ 50%. One thousand and twenty-six consecutive patients were included. The objective response rate (ORR) was 44.5% (95% CI 40.2–49.1), while the median progression free survival (PFS) and overall survival (OS) were 7.9 months (95% CI 6.9–9.5; 599 events) and 17.2 months (95% CI 15.3–22.3; 598 censored patients), respectively. ECOG-PS ≥ 2 (p
- Published
- 2020
26. Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression >= 50%: a multicenter study with external validation
- Author
-
Alessio Cortellini, Miriam Grazia Ferrara, Giovanni Mansueto, Sebastiano Buti, Francesco Passiglia, Francesco Grossi, Luigi Della Gravara, Alain Gelibter, Lorenza Landi, Annamaria Catino, Simona Scodes, Francesca Rastelli, Carlo Genova, Danilo Rocco, Mario Occhipinti, Mariangela Torniai, Federica Zoratto, Pamela Pizzutilo, Diego Cortinovis, Pietro Di Marino, Fausto Petrelli, Vincenzo Di Noia, Alfredo Addeo, Giampiero Porzio, Rita Chiari, Serena Ricciardi, Michele De Tursi, Alex Friedlaender, Marcello Tiseo, Raffaele Giusti, Giorgia Guaitoli, Giuseppe Luigi Banna, Emilio Bria, Maria Rita Migliorino, Joachim G.J.V. Aerts, Marco Filetti, Alessandro De Toma, Diego Signorelli, Giada Targato, Corrado Ficorella, Olga Nigro, Fausto Barbieri, Marco Russano, Biagio Ricciuti, Luca Cantini, Francesca Mazzoni, Fabrizio Tabbò, Alessandro Morabito, Fabrizio Citarella, Alessandro Inno, and Pulmonary Medicine
- Subjects
0301 basic medicine ,Oncology ,Adult ,Male ,Cancer Research ,medicine.medical_specialty ,Lung Neoplasms ,First line ,medicine.medical_treatment ,Immunology ,Pembrolizumab ,Overweight ,Antibodies, Monoclonal, Humanized ,B7-H1 Antigen ,Body Mass Index ,03 medical and health sciences ,0302 clinical medicine ,immunotherapy ,oncology ,Internal medicine ,Carcinoma, Non-Small-Cell Lung ,Immunology and Allergy ,Medicine ,Humans ,Obesity ,RC254-282 ,Aged ,Pharmacology ,Aged, 80 and over ,Clinical/Translational Cancer Immunotherapy ,Chemotherapy ,business.industry ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Middle Aged ,medicine.disease ,030104 developmental biology ,Multicenter study ,030220 oncology & carcinogenesis ,Cohort ,Molecular Medicine ,Female ,medicine.symptom ,business ,Body mass index - Abstract
BackgroundThe association between obesity and outcomes in patients receiving programmed death-1/programmed death ligand-1 (PD-L1) checkpoint inhibitors has already been confirmed in pre-treated non-small cell lung cancer (NSCLC) patients, regardless of PD-L1 tumor expression.MethodsWe present the outcomes analysis according to baseline body mass index (BMI) and BMI variation in a large cohort of metastatic NSCLC patients with a PD-L1 expression ≥50%, receiving first line pembrolizumab. We also evaluated a control cohort of metastatic NSCLC patients treated with first line platinum-based chemotherapy. Normal weight was set as control group.Results962 patients and 426 patients were included in the pembrolizumab and chemotherapy cohorts, respectively. Obese patients had a significantly higher objective response rate (ORR) (OR=1.61 (95% CI: 1.04–2.50)) in the pembrolizumab cohort, while overweight patients had a significantly lower ORR (OR=0.59 (95% CI: 0.37–0.92)) within the chemotherapy cohort. Obese patients had a significantly longer progression-free survival (PFS) (HR=0.61 (95% CI: 0.45–0.82)) in the pembrolizumab cohort. Conversely, they had a significantly shorter PFS in the chemotherapy cohort (HR=1.27 (95% CI: 1.01–1.60)). Obese patients had a significantly longer overall survival (OS) within the pembrolizumab cohort (HR=0.70 (95% CI: 0.49–0.99)), while no significant differences according to baseline BMI were found in the chemotherapy cohort. BMI variation significantly affected ORR, PFS and OS in both the pembrolizumab and the chemotherapy cohorts.ConclusionsBaseline obesity is associated to significantly improved ORR, PFS and OS in metastatic NSCLC patients with a PD-L1 expression of ≥50%, receiving first line pembrolizumab, but not among patients treated with chemotherapy. BMI variation is also significantly related to clinical outcomes.
- Published
- 2020
27. Breath Analysis for Early Detection of Malignant Pleural Mesothelioma: Volatile Organic Compounds (VOCs) Determination and Possible Biochemical Pathways
- Author
-
Teresa Mongelli, Annamaria Catino, Roberto Bellotti, Alessia Di Gilio, Jolanda Palmisani, Gianluigi de Gennaro, Domenico Galetta, Niccolò Varesano, Laura Facchini, Angela Lombardi, and Sabina Tangaro
- Subjects
0301 basic medicine ,Malignant Pleural Mesothelioma (MPM) ,Cancer Research ,medicine.medical_specialty ,Diagnostic methods ,Large population ,Early detection ,lcsh:RC254-282 ,Gastroenterology ,Asymptomatic ,Article ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Medicine ,metabolic pathways ,TD-GC/MS ,Volatile Organic Compounds (VOCs) ,breath analysis ,machine learning ,business.industry ,Pleural mesothelioma ,Advanced stage ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,030104 developmental biology ,Oncology ,Breath gas analysis ,Late diagnosis ,030220 oncology & carcinogenesis ,medicine.symptom ,business - Abstract
Malignant pleural mesothelioma (MPM) is a rare neoplasm, mainly caused by asbestos exposure, with a high mortality rate. The management of patients with MPM is controversial due to a long latency period between exposure and diagnosis and because of non-specific symptoms generally appearing at advanced stage of the disease. Breath analysis, aimed at the identification of diagnostic Volatile Organic Compounds (VOCs) pattern in exhaled breath, is believed to improve early detection of MPM. Therefore, in this study, breath samples from 14 MPM patients and 20 healthy controls (HC) were collected and analyzed by Thermal Desorption-Gas Chromatography-Mass Spectrometry (TD-GC/MS). Nonparametric test allowed to identify the most weighting variables to discriminate between MPM and HC breath samples and multivariate statistics were applied. Considering that MPM is an aggressive neoplasm leading to a late diagnosis and thus the recruitment of patients is very difficult, a promising data mining approach was developed and validated in order to discriminate between MPM patients and healthy controls, even if no large population data are available. Three different machine learning algorithms were applied to perform the classification task with a leave-one-out cross-validation approach, leading to remarkable results (Area Under Curve AUC = 93%). Ten VOCs, such as ketones, alkanes and methylate derivates, as well as hydrocarbons, were able to discriminate between MPM patients and healthy controls and for each compound which resulted diagnostic for MPM, the metabolic pathway was studied in order to identify the link between VOC and the neoplasm. Moreover, five breath samples from asymptomatic asbestos-exposed persons (AEx) were exploratively analyzed, processed and tested by the validated statistical method as blinded samples in order to evaluate the performance for the early recognition of patients affected by MPM among asbestos-exposed persons. Good agreement was found between the information obtained by gold-standard diagnostic methods such as computed tomography CT and model output.
- Published
- 2020
28. Development of Complex Renal Cysts during Crizotinib Treatment and Also during Alectinib Treatment: A Possible Drug Class Effect?
- Author
-
Anna Maria Catino, Annunziata Ferrante, Pamela Pizzutilo, Vito Longo, Pietro Gatti, Gabriela Delbene, F. Pesola, Michele Montrone, and Domenico Galetta
- Subjects
Pulmonary and Respiratory Medicine ,Alectinib ,Oncology ,medicine.medical_specialty ,Crizotinib ,business.industry ,Carbazoles ,Antineoplastic Agents ,Kidney Diseases, Cystic ,Drug class ,Piperidines ,Renal cysts ,Internal medicine ,medicine ,Humans ,business ,medicine.drug - Published
- 2019
29. Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer
- Author
-
Yinghong Wang, Pamela Pizzutilo, Marco Filetti, Amin Nassar, Carolyn J Presley, Christopher J. Hoimes, Paolo A. Ascierto, Sebastiano Buti, Andrea Botticelli, Domenico Mallardo, Haocan Song, Maria Giovanna Dal Bello, Caroline A. Nebhan, Neha Debnath, Foteini Kalofonou, Melissa Bersanelli, Giuseppe Lamberti, Carlo Genova, Thomas U. Marron, Ella Daniels, Vito Vanella, Douglas B. Johnson, Annamaria Catino, Nikhil H. Ramaiya, Rebecca Irlmeier, Raffaele Giusti, Anwaar Saeed, Tamara A. Sussman, Biagio Ricciuti, Dwight H. Owen, Maluki Radford, Toni K. Choueiri, Chiara Casartelli, Domenico Galetta, Shravanti Macherla, David J. Pinato, Paolo Marchetti, Alessio Cortellini, Weijie Ma, Sarah Abou Alaiwi, Fei Ye, Akiva Diamond, Abdul Rafeh Naqash, Asrar Alahmadi, and Teja Ganta
- Subjects
Cancer Research ,medicine.medical_specialty ,Lung Neoplasms ,Population ,Cohort Studies ,Carcinoma, Non-Small-Cell Lung ,Internal medicine ,Humans ,Medicine ,education ,Adverse effect ,Immune Checkpoint Inhibitors ,Aged ,Retrospective Studies ,Aged, 80 and over ,education.field_of_study ,business.industry ,Brief Report ,Cancer ,Common Terminology Criteria for Adverse Events ,Retrospective cohort study ,medicine.disease ,Discontinuation ,Oncology ,Cohort ,business ,Cohort study - Abstract
IMPORTANCE: Geriatric (aged ≥80 years) patients are historically underrepresented in cancer clinical trials. Little is known about the efficacy of immune checkpoint inhibitors (ICIs) in geriatric patients. These agents are associated with immune-related adverse events (irAEs), which may be particularly associated with morbidity in this population. OBJECTIVE: To provide insight into the clinical outcomes and safety of ICIs among geriatric patients (aged ≥80 years) with cancer. DESIGN, SETTING, AND PARTICIPANTS: A Multicenter, international retrospective study of 928 geriatric patients with different tumors treated with single-agent ICIs between 2010 to 2019 from 18 academic centers in the US and Europe. Analyses were conducted from January 2021 to April 2021. MAIN OUTCOMES AND MEASURES: Clinical outcomes and irAE patterns in geriatric patients treated with single-agent ICIs. RESULTS: Median (range) age of the 928 patients at ICI initiation was 83.0 (75.8-97.0) years. Most patients (806 [86.9%]) were treated with anti–programmed cell death 1 therapy. Among the full cohort, the 3 most common tumors were non–small cell lung cancer (NSCLC, 345 [37.2%]), melanoma (329 [35.5%]), and genitourinary (GU) tumors (153 [16.5%]). Objective response rates for patients with NSCLC, melanoma, and GU tumors were 32.2%, 39.3%, and 26.2%, respectively. Median PFS and OS, respectively, were 6.7 and 10.9 months (NSCLC), 11.1 and 30.0 months (melanoma), and 6.0 and 15.0 months (GU). Within histologically specific subgroups (NSCLC, melanoma, and GU), clinical outcomes were similar across age subgroups (aged
- Published
- 2021
30. FP06.04 Psychological Distress in Outpatients with Lymphoma, Lung and Breast Cancer during COVID-19 pandemic
- Author
-
G. Loseto, D. Ricci, A. Guarini, A. Latorre, Francesco Giotta, C. Minoia, E. Silvestris, F. Pesola, A. Mastrandrea, Pamela Pizzutilo, Vito Longo, Annamaria Catino, G. Opinto, Claudia Cormio, D. Bafunno, Miriam Dellino, Francesca Romito, Michele Montrone, and Domenico Galetta
- Subjects
Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,education.field_of_study ,business.industry ,Population ,Cancer ,medicine.disease ,Hospital Anxiety and Depression Scale ,Distress ,Breast cancer ,Oncology ,Internal medicine ,Fp06 Palliative and Supportive Care ,medicine ,Anxiety ,medicine.symptom ,Lung cancer ,education ,business ,Depression (differential diagnoses) - Abstract
Introduction: The psychological impact of the lockdown experienced during the COVID-19 pandemic has been found detrimental for the general population, but it has still not been evaluated in cancer patients We have investigated the psychological status of outpatients receiving anti-neoplastic treatmentduring the lockdown in a non-COVID Cancer Center, with the following aims: to measure the levels of post-traumatic stress symptoms, depression and anxiety, to compare patients with different diagnosis A further objective was to compare the anxiety and depression levels between cancer patients before and after the emergency assuming an increase in distress in cancer patients in this period due to the health emergency Methods: Outpatients attending the IRCCS "Giovanni Paolo II" in Bari for their therapy were asked to complete these questionnaires: The Hospital Anxiety and Depression Scale (HADs) and the Impact of Event Scale-Revised (IES-r) Worries regarding the COVID-19 on patients’ lives, socio-demographic and clinical details were investigated using a brief structured questionnaire Results: One-hundred seventy-six outpatients (n 59 with lung cancer, n 40 with breast cancer, n 77 with lymphoma) were enrolled Mean age was 57 9 y o (SD ±14);48% were male We found that 54,4% of patients were above the cut-off (score≥16) for HADS general scale The mean-IES-R score of patients was 25 (SD±17), with 22 8% indicating severe level of PTDS The HADS-D has been found significantly correlated with IES-R (r= 0 35;p
- Published
- 2021
31. P75.14 Gender-Related Safety and Outcome in Advanced NSCLC Patients Treated with Immune Checkpoint-Inhibitors. A Real-World Experience
- Author
-
D. Ricci, Pamela Pizzutilo, A. Zacheo, Annamaria Catino, I. Marech, P. Petrillo, V. Lamorgese, F. Pesola, A. Mastrandrea, Michele Montrone, Domenico Galetta, Niccolò Varesano, Vito Longo, and D. Bafunno
- Subjects
Pulmonary and Respiratory Medicine ,Oncology ,medicine.medical_specialty ,business.industry ,Immune checkpoint inhibitors ,Internal medicine ,Medicine ,business ,Gender related ,Outcome (game theory) - Published
- 2021
32. P78.12 A Rare Case of Dermatomyositis as Late Immune-Related Toxicity During Anti-PD1 Treatment for Advanced Lung Cancer
- Author
-
L. Lospalluti, G. Cazzato, Pamela Pizzutilo, D. Ricci, F. Pesola, A. Mastrandrea, Annamaria Catino, Vito Longo, F. Ambrogio, Michele Montrone, M. Tampoia, and Domenico Galetta
- Subjects
Pulmonary and Respiratory Medicine ,Immune system ,Oncology ,business.industry ,Immunology ,Toxicity ,Rare case ,Medicine ,Dermatomyositis ,business ,Anti pd1 ,medicine.disease ,Lung cancer - Published
- 2021
33. P40.01 Tobacco use in Adolescence and Associated Factors: Products, School, Family, Peers and Movies in Pandemic Period
- Author
-
Annamaria Catino, F. Pesola, A. Mastrandrea, Pamela Pizzutilo, Michele Montrone, D. Bafunno, A. Zacheo, D. Ricci, V. Lamorgese, S. Cassiano, Vito Longo, I. Marech, P. Petrillo, Domenico Galetta, and Niccolò Varesano
- Subjects
Pulmonary and Respiratory Medicine ,Smoke ,Secondary prevention ,Tobacco use ,Coronavirus disease 2019 (COVID-19) ,business.industry ,Quit smoking ,Oncology ,Cigarette smoking ,Pandemic ,Medicine ,School environment ,business ,Demography - Abstract
Introduction: Tobacco smoking among adolescents is still frequent and stalling in the last decades, so the main purpose of this research is to know if the COVID-19 pandemic had an impact on adolescents' perceptions regarding smoking We investigated: 1) the prevalence of active cigarette smoking;2) if smoking of parents and friends and school environment influences the choice to smoke;3) if the students capture the presence of images of smoking in films;4) the level of concern of the younger people regarding the association between Covid-19 disease and smoke Methods: 719 students (65% boys, aged 13-19 years, from the high school, technical and professional institutes) filled an anonymous questionnaire (31-item), during Covid-lockdown Results: The students have been subdivided into the following categories: daily smokers (12 8%), occasional (30 3%), former (8 8%) and never smokers (48 1%) 52% of students have smoked at least once (n s for gender) Interestingly, over time the probability of starting to smoke decreases (fig1) Furthermore, the students who start smoking early tend to smoke daily (r=-0 13;p < 0 01) and more cigarettes (r=-0 30;p < 0 01) 83% of students start smoking out of curiosity and a spirit of adventure, consuming 1 to 4 cigarettes daily Moreover 30% of them would want to quit but failed;27% never thought about it;while 44% report that they will quit smoking in a few years 59% consume manufactured cigarettes, 36% smoke rolling tobacco;3% use HNB and 2% e-cigarettes The type of cigarettes considered less harmful are electronic cigarettes 68% of the student smokers have in turn someone in the family who smokes, on the contrary only 37 5% of non-smoking students have parent smokers Considering only the students who smoked at least once, 65% replied that someone among friends smoke, while only 4% of no-smokers have smoking friends Finally, the adolescents attending professional institutes smoke daily and more cigarettes (F (2, 368)=5 32;p
- Published
- 2021
34. P75.21 Impact of Diagnosis and Treatment of Concurrent Infections during Immunotherapy in Advanced Lung Cancer: A Retrospective Cohort Study
- Author
-
I. Marech, Laura Monno, Annamaria Catino, Domenico Galetta, Fabio Signorile, G. Angarano, S. Cassiano, V. Lamorgese, Pamela Pizzutilo, Davide Fiore Bavaro, Annalisa Saracino, and F. Pesola
- Subjects
Pulmonary and Respiratory Medicine ,Oncology ,medicine.medical_specialty ,business.industry ,Internal medicine ,medicine.medical_treatment ,medicine ,Retrospective cohort study ,Immunotherapy ,business ,Lung cancer ,medicine.disease - Published
- 2021
35. Pathologic Grading of Malignant Pleural Mesothelioma: An Evidence-Based Proposal
- Author
-
Nicola Fusco, Izidor Kern, Anna Scattone, Eugenio Maiorano, Nikolaos Papanikolaou, Giuseppe Pelosi, Gabriella Serio, Silvano Bosari, Alessandra Punzi, Patrick Maisonneuve, Fausto Barbieri, Mauro Papotti, Federico Rea, Giulio Rossi, Lorenzo Rosso, Giulia Pasello, Angelica Sonzogni, Anna Maria Catino, Antonio Pennella, Silvia Novello, Francesca Lunardi, Fiorella Calabrese, Federica Pezzuto, Luisella Righi, Stefano Ferrero, Sergio Harari, Elena Prisciandaro, Angela De Palma, Adriana Albini, Enrica Capelletto, Andrea Marzullo, Domenica Cavone, Pelosi, G, Papotti, M, Righi, L, Rossi, G, Ferrero, S, Bosari, S, Calabrese, F, Kern, I, Maisonneuve, P, Sonzogni, A, Albini, A, Harari, S, Barbieri, F, Capelletto, E, Catino, A, Cavone, D, De Palma, A, Fusco, N, Lunardi, F, Maiorano, E, Marzullo, A, Novello, S, Papanikolaou, N, Pasello, G, Pennella, A, Pezzuto, F, Punzi, A, Prisciandaro, E, Rea, F, Rosso, L, Scattone, A, and Serio, G
- Subjects
Male ,0301 basic medicine ,Mesothelioma ,PREDICTOR ,Lung Neoplasms ,Multivariate analysis ,Survival ,Respiratory System ,carcinoma ,GUIDELINES ,preživetje ,PROGNOSTIC-FACTORS ,0302 clinical medicine ,Grading (education) ,ocenjevanje ,Hazard ratio ,Score ,Grading ,Pleura ,Oncology ,Pulmonary and Respiratory Medicine ,NUCLEAR ANTIGEN ,Middle Aged ,CANCER ,pleura ,030220 oncology & carcinogenesis ,Female ,Radiology ,Life Sciences & Biomedicine ,dirros.openscience.si/admin/GradivoDatoteke.php?id=12688lioma [mesothehttp] ,medicine.medical_specialty ,Pleural Neoplasms ,ORGANIZATION ,survival ,03 medical and health sciences ,MITOTIC INDEX ,medicine ,Humans ,udc:616.2 ,Retrospective Studies ,Cancer staging ,Science & Technology ,Receiver operating characteristic ,business.industry ,Mesothelioma, Malignant ,Retrospective cohort study ,grading ,karcinom ,medicine.disease ,Clinical trial ,030104 developmental biology ,plevra ,mezoteliom ,Neoplasm Grading ,business ,NEUROENDOCRINE TUMORS ,LUNG - Abstract
INTRODUCTION: A pathologic grading system (PGS) for malignant pleural mesothelioma (MPM) is warranted to better identify different risk categories of patients, plan therapeutic options, and activate clinical trials. METHODS: A series of 940 patients with MPM (328 in a training set and 612 in a validation set) that was diagnosed between October 1980 and June 2015 at the participant institutions was retrospectively assembled. A PGS was constructed by attributing to each histologic parameter, independent at multivariate analysis with excellent reproducibility (κ > 0.75), different scores based on the increase in corresponding hazard ratios. The relevant PGS score thus ranged from 0 to 8 points for individual patients with MPM. CONCLUSIONS: The PGS was constructed by taking into consideration the histological subtyping of MPM (epithelioid/biphasic = 0 points; sarcomatoid = 2 points), necrosis (absent = 0 points versus present = 1 point), mitotic count per 1 mm2 (cutoffs as follows: 1-2 = 0 points, 3-5 = 1 point, 6-9 = 2 points, or ≥10 = 4 points), and Ki-67 labeling index based on 2000 cells (
- Published
- 2018
36. Phase II, noncomparative, open label, multicenter, study of osimertinib, in patients with locally advanced or metastatic EGFR mutated, T790M undetectable or unknown non-small cell lung cancer (Stage IIIB-IV) after no immediate prior EGFR TKI (OSIRIS study)
- Author
-
Francesco Verderame, Vito Barbieri, Hector Soto Parra, Annamaria Catino, Francesco Ferraù, Rossana Avola, Marco Aiello, Francesca Spinnato, F. Latteri, Lucia Gozzo, Oriana Valerio, Enrica Capelletto, Laura Noto, Domenico Galetta, Maria Rita Migliorino, Pierfrancesco Tassone, A.M. Morelli, Silvia Novello, and Serena Ricciardi
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,business.industry ,Locally advanced ,medicine.disease ,respiratory tract diseases ,Egfr tki ,T790M ,Multicenter study ,Internal medicine ,medicine ,In patient ,Osimertinib ,Non small cell ,Lung cancer ,business - Abstract
e21116 Background: Osimertinib (OSI) is a potent irreversible EGFR TKI approved for 1st line therapy advanced EGFR+ NSCLC and for 2nd line T790M+ pts. The AURA trial showed promising results even in pts with T790M- NSCLC after no immediate prior OSI in locally advanced or metastatic EGFR+ NSCLC, T790M undetectable or unknown, after 1st line EGFR TKI and subsequent chemotherapy. Methods: This phase II trial was performed to investigate the role OSI in locally advanced or metastatic EGFR+ NSCLC, T790M undetectable or unknown, after 1st line EGFR TKI (1 or 2 generation) and subsequent chemotherapy. Eligible pts (M or F, > 18 years, ECOG 0-2) received OSI (80 mg/day) until disease progression or unacceptable toxicity. Objective response rate (ORR) was the primary endopoint. Assuming a 10% attrition rate, 90 pts were planned to be enrolled according to the Optimal Simon’s 2 stage design. In the first stage, 32 pts were planned to be accrued, and if ≤ 3 responses were observed the study would be stopped. Otherwise, 49 additional pts were planned to be accrued. The null hypothesis would have been rejected if ≥ 12 responses were observed. This design yields a type I error rate of 0.05 and 80% power. Results: From May 2017 to October 2020, a total of 54 pts were enrolled (17 M and 37 F, mean age 66 years). The study was stopped early due to an extremely slow enrolment rate. However, the ORR of 31.5% (95% CI 19.5% - 45.5%) was significantly higher than the null hypothesis of 9% (p
- Published
- 2021
37. Molecular profiling in Italian patients with advanced non-small-cell lung cancer: An observational prospective study
- Author
-
Vieri Scotti, Salvatore Pisconti, Paolo Graziano, Evaristo Maiello, Ferdinando Riccardi, F. Arizio, Emilio Bria, Domenico Galetta, Giulio Rossi, Marcello Tiseo, Diego Cortinovis, Silvia Novello, Lucio Buffoni, Anna Ceribelli, Tindara Franchina, Maria Rita Migliorino, Angelo Delmonte, Elisa Gobbini, Paola Bordi, Vanesa Gregorc, Massimo Di Maio, Annamaria Catino, and Antonio Rossi
- Subjects
Adult ,Male ,Pulmonary and Respiratory Medicine ,Oncology ,Cancer Research ,medicine.medical_specialty ,Lung Neoplasms ,medicine.drug_class ,Afatinib ,Kaplan-Meier Estimate ,medicine.disease_cause ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Gefitinib ,Carcinoma, Non-Small-Cell Lung ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,ROS1 ,Humans ,Molecular Targeted Therapy ,Prospective Studies ,030212 general & internal medicine ,Prospective cohort study ,Lung cancer ,Protein Kinase Inhibitors ,Aged ,Neoplasm Staging ,Aged, 80 and over ,Gene Rearrangement ,Crizotinib ,business.industry ,Gene Expression Profiling ,Middle Aged ,medicine.disease ,Surgery ,Molecular profiling ,ALK inhibitor ,Treatment Outcome ,Italy ,030220 oncology & carcinogenesis ,Mutation ,Female ,KRAS ,Transcriptome ,business ,medicine.drug - Abstract
Objectives Molecular profiling of advanced non-small-cell lung cancer (NSCLC) is recommended according to European and Italian guidelines. However, molecular routine assessment remains still heterogeneous. This observational study aimed to take a picture of the real clinical practice in molecular testing and therapeutic choices in advanced Italian NSCLCs. Materials and methods This study prospectively enrolled newly diagnosed advanced or recurrent NSCLCs referred to 38 Italian centres, from November 2014 to November 2015. Information regarding molecular profiling and treatment choices were collected. Description of patients’ outcome included overall survival (OS), progression-free survival in first (PFS1) and second-line (PFS2). Results and conclusion Among 1787 patients enrolled, 1388 (78%) performed at least one molecular analysis during the history of disease: 76% were tested for EGFR, 53% for ALK, 27% for KRAS, 16% for ROS1, 14% for BRAF, 5% for HER2, 4% for MET and 1% for FGFR. The remaining 399 patients (22.3%) did not receive any molecular test. Among patients receiving at least one molecular analysis, 583 (42%) presented a molecular alteration. Considering EGFR mutated and/or ALK rearranged patients (402), for which target agents were routinely reimbursed at time of study in Italy, the 86% received a personalized treatment as first and/or second line: the 90% (286) of EGFR mutants received an EGFR tyrosine kinase inhibitor, mostly gefitinib (41.1%) or afatinib (36.4%) while 74% (62) of ALK translocated patients received an ALK inhibitor, mostly crizotinib (64%). Median OS was 9.34 months (95% CI 8.62–10.0), median PFS1 was 4.61 months (95%CI 4.31–4.84) and median PFS2 was 2.76 months (95%CI 2.57–3.19). In the Italian clinical practice, routine molecular assessment was largely applied in NSCLC patients, according to national guidelines, but a low level of ALK test was reached. Most of EGFR mutants an ALK rearranged patients received a personalized treatment as first and/or second line.
- Published
- 2017
38. Prospective Evaluation of Sunitinib-Induced Cardiotoxicity in Patients with Metastatic Renal Cell Carcinoma
- Author
-
Naomi B. Haas, Steven M. Ewer, David Hyman, Vivek Narayan, Anna Catino, Chantal ElAmm, Mary E. Putt, Daniel J. Lenihan, Neeraj Agarwal, James C. Fang, Le Wang, Bonnie Ky, Brian S. Finkelman, Igor Puzanov, Stephen M. Keefe, Hari K. Narayan, and Amanda M. Smith
- Subjects
Male ,Cancer Research ,medicine.medical_specialty ,Indoles ,Urology ,030204 cardiovascular system & hematology ,urologic and male genital diseases ,Article ,Ventricular Dysfunction, Left ,03 medical and health sciences ,0302 clinical medicine ,Renal cell carcinoma ,Natriuretic Peptide, Brain ,Sunitinib ,medicine ,Carcinoma ,Humans ,Pyrroles ,Prospective cohort study ,Carcinoma, Renal Cell ,Aged ,Heart Failure ,Cardiotoxicity ,Ejection fraction ,business.industry ,Troponin I ,Cancer ,Middle Aged ,medicine.disease ,Surgery ,Oncology ,Echocardiography ,030220 oncology & carcinogenesis ,Biomarker (medicine) ,Female ,business ,medicine.drug - Abstract
Purpose: To prospectively evaluate cardiotoxicity risk with sunitinib in metastatic renal cell carcinoma (mRCC) routine clinical practice using comprehensive echocardiography and biomarker phenotyping. Experimental Design: In a multicenter prospective study of 90 patients with mRCC, echocardiography and biomarkers of cardiovascular injury and stress were quantified at baseline, 3.5, 15, and 33 weeks following sunitinib initiation. These “on-drug” visits corresponded to cycles 1, 3, and 6, respectively. Left ventricular (LV) dysfunction was defined as an absolute decline in LV ejection fraction (LVEF) by ≥10% to a value of Results: The predicted risk of LV dysfunction by cycle 6 was 9.7% (95% confidence interval, 3%–17%). The majority of events occurred in the first treatment cycle. This risk diminished to 5% and 2% in patients who had not experienced dysfunction by the completion of cycles 1 and 3, respectively. All evaluable patients who experienced LV dysfunction had subsequent improvement in LVEF with careful management. Six patients (6.7%) developed hsTnI elevations >21.5 pg/mL, and 11 additional patients (12.2%) developed BNP elevations >100 pg/mL. These elevations similarly tended to occur early and resolved over time. Conclusions: On average, patients with mRCC receiving sunitinib exhibit modest declines in LVEF and nonsignificant changes in hsTnI and BNP. However, approximately 9.7% to 18.9% of patients develop more substantive abnormalities. These changes occur early and are largely recoverable with careful management. Clin Cancer Res; 23(14); 3601–9. ©2017 AACR.
- Published
- 2017
39. KRAS-Driven Lung Adenocarcinoma and B Cell Infiltration: Novel Insights for Immunotherapy
- Author
-
Daniela Petriella, Gabriella Del Bene, Rosamaria Pinto, Simona De Summa, Annamaria Catino, Pamela Pizzutilo, Francesco Alfredo Zito, Rosanna Lacalamita, Antonia Zonno, Stefania Tommasi, Michele Montrone, and Maria Antonietta Botticella
- Subjects
0301 basic medicine ,LUAD ,Cancer Research ,In silico ,medicine.medical_treatment ,Biology ,medicine.disease_cause ,Malignancy ,lcsh:RC254-282 ,Article ,03 medical and health sciences ,0302 clinical medicine ,medicine ,KRAS ,tumor microenvironment ,Lung cancer ,B cell ,Tumor microenvironment ,B cells ,Immunotherapy ,medicine.disease ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,030104 developmental biology ,medicine.anatomical_structure ,Oncology ,030220 oncology & carcinogenesis ,Cancer research ,Adenocarcinoma ,immunotherapy - Abstract
Non-small-cell lung cancer, histologically classified into adenocarcinoma (AD) and squamous cell carcinoma, is one of the most deadly malignancies worldwide. Lung AD (LUAD) could benefit of a plethora of target therapies and, in the last few years, also of immunotherapies. Here we focused on a real-life cohort of LUAD and The Cancer Genome Atlas (TCGA)-LUAD dataset aiming to gain insights into the immune contexture of such a malignancy. We explored the mutational status of 41 genes and the expression of 94 genes, related to immune-checkpoint, inflammation, and stromal microenvironment. Surprisingly, we found that our cohort has a very low mutational burden if we consider our panel as its surrogate. Regarding gene expression data, we identified 31 genes significantly deregulated in tumor tissues compared with a pool of normal samples. Unsupervised hierarchical clustering of the deregulated genes is able to identify two clusters of tumor samples, differently enriched in alterations in actionable genes. In particular, we identified a cluster enriched in patients carrying KRAS alterations. In silico deconvolution, that is the inferring of tumor microenvironment composition by gene expression data, through TIMER algorithm has been performed to explore immune microenvironment. Estimation performed on our gene expression matrix showed that B cell infiltration is lower in the KRAS-mutated enriched cluster, as in the TCGA-LUAD dataset. Such a finding has been validated in situ through immunohistochemistry in an independent cohort. Moreover, cases in LUAD-TCGA with low B cell infiltration have a significantly worse overall survival than those with higher levels. In the real-life cohort we observed that cases belonging to cluster enriched in KRAS-mutated patients have a poor outcome. LUAD driven by KRAS mutation represents an unmet clinical need, being refractory to pharmacological inhibition. Our results link KRAS mutations to B cell infiltration. Thus, the present findings could be helpful in a better definition of immunotherapeutic approaches for KRAS mutated patients.
- Published
- 2019
40. Women With Synchronous or Metachronous Lung and Ovarian Cancer: A Multi-Institutional Report
- Author
-
Massimo Di Maio, Rita Chiari, Giorgio Valabrega, Annamaria Catino, Annapaola Mariniello, Fausto Barbieri, Fabiana Letizia Cecere, Silvia Novello, Matteo Giaj-Levra, Clizia Zichi, Eleonora Ghisoni, Alain Gelibter, Hector Soto Parra, Luisella Righi, and Alessandro Del Conte
- Subjects
Oncology ,Adult ,Cancer Research ,medicine.medical_specialty ,Lung Neoplasms ,Homologous recombination deficiency ,Immunohistochemistry ,Lung cancer ,Ovarian cancer ,Women ,Adenocarcinoma ,General Biochemistry, Genetics and Molecular Biology ,Piperazines ,Olaparib ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Internal medicine ,medicine ,Overall survival ,Humans ,Pathological ,Aged ,Retrospective Studies ,Pharmacology ,Ovarian Neoplasms ,Lung ,business.industry ,BRCA1 Protein ,Carcinoma ,Middle Aged ,medicine.disease ,Serous fluid ,medicine.anatomical_structure ,chemistry ,030220 oncology & carcinogenesis ,Mutation ,Phthalazines ,Female ,business ,Research Article - Abstract
Background/aim Double diagnosis of lung cancer (LC) and ovarian cancer (OC) is rare. Here, we describe patients with synchronous/metachronous LC and OC to identify common clinical and pathological patterns. Patients and methods Clinical, pathological and molecular data of patients diagnosed and treated at 30 European Institutions from 2008 to 2018 were retrieved and analysed. Whenever tissue was available, centralized pathology revision was performed. Results A total of 19 cases were found; one was excluded at pathology revision. Most LCs were adenocarcinomas (15/18) and most OCs were high-grade serous (15/18) carcinomas. Of the 9 patients analysed, 7 carried oncogene-addicted LC (4 EGFR, 1 B-RAF and 2 ALK) and five out of 7 carried BRCA mutations. One patient with a germline-BRCA1 mutation received olaparib, resulting in a durable response of both malignancies. Median overall survival was 33 months. Conclusion In our series, most synchronous/metachronous LCs and OCs showed genetic alterations. Further analyses with wide NGS panel could shed light on the biological mechanisms driving their occurrence.
- Published
- 2019
41. Breath Analysis: A Systematic Review of Volatile Organic Compounds (VOCs) in Diagnostic and Therapeutic Management of Pleural Mesothelioma
- Author
-
Laura Facchini, Domenico Galetta, Alessia Di Gilio, Niccolò Varesano, Annamaria Catino, Jolanda Palmisani, Francesca Porcelli, and Gianluigi de Gennaro
- Subjects
0301 basic medicine ,Cancer Research ,medicine.medical_specialty ,volatile organic compounds (VOCs) ,business.industry ,Pleural mesothelioma ,Diagnostic accuracy ,Review ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Data treatment ,lcsh:RC254-282 ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,Oncology ,Breath gas analysis ,030220 oncology & carcinogenesis ,Medicine ,Biomarker (medicine) ,Observational study ,breath analysis ,business ,Intensive care medicine ,malignant pleural mesothelioma (MPM) ,Cohort study - Abstract
Malignant pleural mesothelioma (MPM) is a rare neoplasm related to asbestos exposure and with high mortality rate. The management of patients with MPM is complex and controversial, particularly with regard to early diagnosis. In the last few years, breath analysis has been greatly implemented with this aim. In this review the strengths of breath analysis and preliminary results in searching breath biomarkers of MPM are highlighted and discussed, respectively. Through a systematic electronic literature search, collecting papers published from 2000 until December 2018, fifteen relevant scientific papers were selected. All papers considered were prospective, comparative, observational case–control studies although every single one pilot and based on a relatively small number of samples. The identification of diagnostic VOCs pattern, through breath sample characterization and the statistical data treatment, allows to obtain a strategic information for clinical diagnostics. To date the collected data provide just preliminary information and, despite the promising results and diagnostic accuracy, conclusions cannot be generalized due to the limited number of individuals included in each cohort study. Furthermore none of studies was externally validated, although validation process is a necessary step towards clinical implementation. Breathomics-based biomarker approach should be further explored to confirm and validate preliminary findings and to evaluate its potential role in monitoring the therapeutic response.
- Published
- 2019
42. Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians’ attitudes
- Author
-
Raffaele Giusti, Francesca Rastelli, Rita Chiari, Daniele Santini, Olga Nigro, Miriam Grazia Ferrara, G. Porzio, C. Maggioni, Corrado Ficorella, Diego Cortinovis, Alessandro Follador, Paola Bordi, Marcello Tiseo, Giuseppe Luigi Banna, Marco Filetti, Elisa Sala, Alessandro Tuzi, Mariangela Torniai, Emilio Bria, Domenico Galetta, Daniela Iacono, Alessio Cortellini, Annamaria Catino, Alessandro Leonetti, Fabrizio Citarella, Federica Zoratto, Marco Russano, Maria Rita Migliorino, Marianna Macerelli, Davide Brocco, Biagio Ricciuti, Katia Cannita, Paolo Marchetti, A. De Giglio, Rossana Berardi, P. Pizzutillo, and M. De Tursi
- Subjects
0301 basic medicine ,Oncology ,Health Knowledge, Attitudes, Practice ,Cancer Research ,Multivariate analysis ,medicine.medical_treatment ,carcinoma ,NSCLC ,T790M ,survival analysis ,0302 clinical medicine ,Carcinoma, Non-Small-Cell Lung ,middle aged ,italy ,antineoplastic agents ,80 and over ,Osimertinib ,humans ,Aged, 80 and over ,Univariate analysis ,attitudes ,adult ,Standard treatment ,General Medicine ,acrylamides ,practice ,aged ,female ,030220 oncology & carcinogenesis ,erbb receptors ,aniline compounds ,medicine.medical_specialty ,Beyond progression ,combined modality therapy ,EGFR ,beyond progression ,egfr ,nsclc ,osimertinib ,progression of disease ,t790m ,aged, 80 and over ,carcinoma, non-small-cell lung ,disease progression ,health knowledge, attitudes, practice ,lung neoplasms ,male ,mutation ,treatment outcome ,Progression of disease ,03 medical and health sciences ,Internal medicine ,medicine ,Chemotherapy ,business.industry ,Disease progression ,non-small-cell lung ,030104 developmental biology ,health knowledge ,Multicenter study ,business - Abstract
In most cases, T790M EGFR-positive NSCLC patients receiving osimertinib developed “non-drugable” progression, as the patients with common EGFR-sensitizing mutations were treated with first-line osimertinib. In both settings, chemotherapy represents the standard treatment and local ablative treatments (LATs) are potential useful options in the case of oligo-progression. We conducted a study on “post-progression” (pp) outcomes of T790M EGFR-positive NSCLC patients treated with osimertinib, according to the therapeutic strategy applied: osimertinib beyond progression (± LATs), “switched therapies” or best supportive care only (BSC). 144 consecutive patients were evaluated: 53 (36.8%) did not received post-progression treatments (BSC), while 91 (63.2%) patients received at least 1 subsequent treatment; 50 patients (54.9%) received osimertinib beyond disease progression [19 (20.9%) of them with adjunctive LATs] and 41 (45.1%) a switched therapy. Median ppPFS (progression-free survival) and median ppOS (overall survival) of patients who received osimertinib beyond progression vs. switched therapies were 6.4 months vs. 4.7 months, respectively [HR 0.57 (95% CI 0.35–0.92), p = 0.0239] and 11.3 months vs 7.8 months, respectively [HR 0.57 (95% CI 0.33–0.98), p = 0.0446]. Among patients who received osimertinib beyond progression with and without LATs median ppPFS was 6.4 months and 5.7 months, respectively [HR 0.90 (95% CI 0.68–1.18), p = 0.4560], while median ppOS was 20.2 months and 9.9 months, respectively [HR 0.73 (95% CI 0.52–1.03), p = 0.0748]. At the univariate analysis, the only factor significantly related to the ppPFS was the therapeutic strategy in favor of osimertinib beyond progression (± LATs). Moreover, the only variable which was significantly related to ppOS at the multivariate analysis was osimertinib beyond progression (± LATs). Our study confirmed that in clinical practice, in case of “non-druggable” disease progression, maintaining osimertinib beyond progression (with adjunctive LATs) is an effective option.
- Published
- 2019
43. Real-life results from the overall population and key subgroups within the Italian cohort of nivolumab expanded access program in non-squamous non–small cell lung cancer
- Author
-
Enrico Cortesi, Davide Tassinari, Daniele Turci, Fausto Roila, Diego Signorelli, Annamaria Catino, Lorenza Landi, Francesco Grossi, Luca Toschi, Francesco Cognetti, Alessandro Scoppola, Giuseppe Tonini, Hector Soto Parra, Francesco Gelsomino, G. Puppo, Diana Giannarelli, Lucio Crinò, Antonio Passaro, Carlo Genova, Angelo Delmonte, Serena Ricciardi, and Marcello Tiseo
- Subjects
Compassionate Use Trials ,Male ,0301 basic medicine ,Oncology ,Cancer Research ,real-world ,Lung Neoplasms ,Central Nervous System Neoplasms ,Cohort Studies ,Antineoplastic Agents, Immunological ,0302 clinical medicine ,Carcinoma, Non-Small-Cell Lung ,80 and over ,Non-Small-Cell Lung ,Aged, 80 and over ,education.field_of_study ,non-squamous non–small cell lung cancer ,Liver Neoplasms ,Middle Aged ,Progression-Free Survival ,Survival Rate ,Immunological ,Italy ,expanded access program ,030220 oncology & carcinogenesis ,Cohort ,Female ,immunotherapy ,Nivolumab ,Adult ,medicine.medical_specialty ,Population ,Antineoplastic Agents ,03 medical and health sciences ,Expanded access program ,Immunotherapy ,Non-squamous non–small cell lung cancer ,Real-world ,Aged ,Humans ,Internal medicine ,medicine ,nivolumab ,Progression-free survival ,Lung cancer ,education ,Survival rate ,Survival analysis ,business.industry ,Carcinoma ,medicine.disease ,030104 developmental biology ,Expanded access ,business - Abstract
Background Nivolumab was the first immune checkpoint inhibitor approved for previously treated advanced non–small cell lung cancer (NSCLC). Before its introduction in the market, nivolumab was made available to NSCLC patients through an expanded access program (EAP). Here we present the Italian cohort of patients with non-squamous NSCLC enrolled in a worldwide nivolumab EAP, with subgroup analyses involving elderly patients, patients with central nervous system (CNS) metastases and patients receiving nivolumab beyond progression. Methods Pretreated patients with advanced non-squamous NSCLC received nivolumab at 3 mg/kg every 2 weeks up to 24 months. Efficacy data (investigator-assessed tumour response, progression date and survival) and safety data were collected. Findings 1588 patients were treated across 153 Italian centres. Overall response rate and disease control rate were 18% and 44%, respectively; median overall survival (OS) was 11.3 months (95% CI: 10.2–12.4). Elderly patients (≥70 n = 522; ≥75 n = 232) achieved outcomes similar to the global study population; patients with CNS metastases (n = 409) had an OS of 8.6 months (95% CI: 6.4–10.8), and a 1-year OS rate of 43%. Nivolumab was administered beyond progression to 276 patients (26%), 57 of whom achieved subsequent disease control; the median OS of patients receiving nivolumab beyond progression was 16.2 months (95% CI: 14.0–18.4), while 1-year OS rate was 62%. Interpretation To date, this is the largest clinical experience with nivolumab in a real-world setting. Our data support its use in clinical practice for pretreated non-squamous NSCLC, including patients with older age or CNS metastases.
- Published
- 2019
44. Maintenance with lanreotide in small-cell lung cancer expressing somatostatine receptors: A multicenter, randomized, phase 3 trial
- Author
-
Michele Milella, Annamaria Catino, Luciana Giannone, Francesco Grossi, Diana Giannarelli, Emilio Bria, Adolfo Favaretto, Domenico Galetta, Alessandro Follador, Carlo Genova, Giampaolo Tortora, Erika Rijavec, Gianpiero Fasola, Laura Bonanno, Maximilian Papi, Sara Pilotto, Alessandra Bearz, P. Petrillo, G. Romano, Elisa Roca, and Antonio Santo
- Subjects
0301 basic medicine ,Oncology ,Male ,Cancer Research ,Lung Neoplasms ,Phases of clinical research ,Gene Expression ,Lanreotide ,law.invention ,Efficacy ,chemistry.chemical_compound ,0302 clinical medicine ,Maintenance therapy ,Randomized controlled trial ,law ,Receptors ,80 and over ,Medicine ,Receptors, Somatostatin ,Neoplasm Metastasis ,Aged, 80 and over ,Cyclic ,Standard treatment ,Middle Aged ,Prognosis ,Treatment Outcome ,Italy ,030220 oncology & carcinogenesis ,Female ,Somatostatin ,Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,Randomization ,Maintenance ,Somatostatine analogue ,Small-cell lung cancer ,Aged ,Humans ,Maintenance Chemotherapy ,Neoplasm Staging ,Peptides ,Proportional Hazards Models ,Small Cell Lung Carcinoma ,Peptides, Cyclic ,03 medical and health sciences ,Internal medicine ,Progression-free survival ,Settore MED/06 - ONCOLOGIA MEDICA ,business.industry ,030104 developmental biology ,chemistry ,business - Abstract
Considering the frequent expression of somatostatine receptors, we designed the G04.2011 trial to investigate the efficacy of the somatostatine analogue lanreotide in maintenance for SCLC patients after response to standard treatment.A multicenter, randomized, phase 3 trial was conducted in SCLC expressing somatostatine receptors at baseline Octreoscan, responding after platinum-based chemotherapy with/without radiotherapy. Patients were randomized 1:1 to receive maintenance lanreotide 120 mg subcutaneously every 28 days, up to 1 year or progression versus observation. Randomization was stratified according to stage (limited/extended, LD/ED). The primary end-point was progression-free survival (PFS). Secondary endpoints were overall survival (OS) and safety.Seventy-one patients were randomly assigned (39 to lanreotide, 32 to observation) in 9 Italian institutions. Median PFS was 3.6 (95% CI 3.2-3.9) with lanreotide versus 2.3 months (95% CI 1.7-2.9) with observation (HR 1.51, 95% CI 0.90-2.50; P = 0.11). Stage was an independent predictor for PFS (HR 3.14, 95% CI 1.77-5.57; P 0.0001). Median PFS was 7.0 (95% CI1-13.5) with lanreotide versus 3.8 months (95% CI1-8.6) with observation in LD (P = 0.21), and 3.0 (95% CI 2.2-3.8) versus 2.2 (95% 1.7-2.7) in ED (P = 0.19). Median OS was 9.5 (95% CI 4.8-14.3) with lanreotide versus 4.7 months (95% CI1-16.6) with observation (P = 0.47). Treatment-related adverse events occurred in 28% of patients with lanreotide (grade 3 in two patients).Although survival outcomes were not significantly prolonged with lanreotide as a maintenance in SCLC expressing somatostatin receptors after response to standard treatment, lanreotide showed a slight PFS benefit in LD SCLC deserving further investigations.
- Published
- 2019
45. Italian cohort of the nivolumab EAP in squamous NSCLC: Efficacy and safety in patients with CNS metastases
- Author
-
Milena Vitali, Annamaria Catino, Gennaro Palmiotti, Davide Tassinari, Filippo de Marinis, Paolo Marchetti, Rita Chiari, Antonio Frassoldati, Francesca Sperandi, Francovito Piantedosi, Maria Rita Migliorino, Diana Giannarelli, Antonio Pazzola, Diego Cortinovis, Angelo Delmonte, Francesco Grossi, Francesca Colonese, Armando Santoro, Francesco Verderame, Francesco Cognetti, Carlo Tondini, and Hector Soto Parra
- Subjects
Oncology ,Adult ,Male ,Cancer Research ,medicine.medical_specialty ,Socio-culturale ,PD1 inhibitor ,Central Nervous System Neoplasms ,Cohort Studies ,03 medical and health sciences ,realworld evidence ,0302 clinical medicine ,Internal medicine ,Carcinoma, Non-Small-Cell Lung ,medicine ,Humans ,Progression-free survival ,Lung cancer ,Non-Small-Cell Lung ,Cancer staging ,Aged ,Neoplasm Staging ,Real-world evidence ,business.industry ,Brain Neoplasms ,Carcinoma ,Brain metastases ,General Medicine ,Middle Aged ,medicine.disease ,Clinical trial ,Brain mBrain metastases, immunotherapy, PD1 inhibitor, realworld evidence ,Nivolumab ,Italy ,Blood-Brain Barrier ,030220 oncology & carcinogenesis ,Expanded access ,Cohort ,Brain mBrain metastases ,immunotherapy ,real-world evidence ,Female ,Immunotherapy ,business ,Cohort study - Abstract
Background/aim Brain metastases are an additional challenge in patients with non-small-cell lung cancer (NSCLC) because most chemotherapy agents cannot cross the blood-brain barrier. Nivolumab has demonstrated efficacy in patients with advanced squamous NSCLC, but because patients with central nervous system (CNS) metastases are typically excluded from registration trials, 'field-practice' data are needed. Patients and methods Patients in the Italian cohort of the Expanded Access Program (EAP) who had CNS metastases at baseline were analyzed. Results Thirty-seven patients with CNS metastases received a median of six doses of nivolumab. Three patients (8%) had grade 3-4 adverse events and one patient discontinued due to an adverse event. The objective response rate was 19%. Median overall survival was 5.8 (95% confidence interval=1.9-9.8) months and median progression-free survival was 4.9 (95% confidence interval=2.7-7.1) months. Conclusion The safety and efficacy of nivolumab in patients with CNS metastases appear to be similar to those seen in the overall EAP cohort in Italy.
- Published
- 2019
46. Clinical and prognostic role of matrix metalloproteinase-2, -9 and their inhibitors in breast cancer and liver diseases: A review
- Author
-
Eufemia Savino, Ines Abbate, Annamaria Catino, Gennaro Gadaleta-Caldarola, Antonella Daniele, Francesco Giotta, Porzia Casamassima, Vito Michele Fazio, R. De Luca, C. Oakley, Addolorata Casamassima, Giancarlo Sciortino, and Rosa Divella
- Subjects
0301 basic medicine ,Oncology ,medicine.medical_specialty ,Gelatinases ,Gelatinase A ,Breast Neoplasms ,Disease ,Matrix metalloproteinase ,Biochemistry ,Metastasis ,03 medical and health sciences ,0302 clinical medicine ,Breast cancer ,Internal medicine ,Animals ,Humans ,Medicine ,business.industry ,Liver Neoplasms ,Tissue Inhibitor of Metalloproteinases ,Cell Biology ,Prognosis ,medicine.disease ,030104 developmental biology ,Matrix Metalloproteinase 9 ,030220 oncology & carcinogenesis ,Hepatocellular carcinoma ,Immunology ,Matrix Metalloproteinase 2 ,business ,Breast carcinoma - Abstract
Matrix metalloproteinases are a family of zinc endopeptidases with proteolytic activity against the extracellular matrix components. In particular, two members of this family named Gelatinase A and B, as amply documented in the literature, play a key role in the process of tumor growth/metastasis in breast and hepatocellular carcinoma. Their activity is regulated by Tissue Inhibitor of metalloproteinases-1 and -2, which are the physiological inhibitor of Gelatinases A and B respectively. The aim of this review is to determine the current understanding of the clinical and prognostic role of Metalloproteinases-2 and -9 and their inhibitors in the course of breast cancer and liver diseases. Forty-one articles were selected from PubMed by entering the following keywords: liver diseases, breast cancer, MMP-2, TIMP-2; all articles were read and notes were made regarding the number of enrolled patients, pathology, measures, results and these data were used to write this review. Over-expression of both gelatinases is associated with the relapse of disease, metastasis, shorter overall survival in breast cancer and hepatocellular carcinoma and invasion and progression to tumors in chronic liver diseases, and MMPs/TIMPs ratio could be useful in the follow-up of these patients.
- Published
- 2016
47. EPSILoN: A Prognostic Score Using Clinical and Blood Biomarkers in Advanced Non–Small-cell Lung Cancer Treated With Immunotherapy
- Author
-
Pamela Pizzutilo, V. Lamorgese, D. Bafunno, Sara Elena Rebuzzi, Vittoria Lapadula, Arsela Prelaj, Vito Longo, Domenico Galetta, Niccolò Varesano, Massimo Bilancia, F. Pesola, P. Petrillo, Annamaria Catino, A. Mastrandrea, Michele Montrone, Donatella Ricci, Gabriella Del Bene, and Flavio Cassano
- Subjects
Male ,0301 basic medicine ,Oncology ,Cancer Research ,Lung Neoplasms ,Multivariate analysis ,Neutrophils ,medicine.medical_treatment ,Lymphocyte ,NSCLC ,Prognostic score ,chemistry.chemical_compound ,0302 clinical medicine ,Carcinoma, Non-Small-Cell Lung ,Leukocytes ,Lymphocytes ,Aged, 80 and over ,Prognostic factor ,Score ,Middle Aged ,Prognosis ,Survival Rate ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Carcinoma, Squamous Cell ,Female ,Immunotherapy ,Algorithms ,Adult ,Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,Peripheral blood ,03 medical and health sciences ,Internal medicine ,Lactate dehydrogenase ,Biomarkers, Tumor ,medicine ,Humans ,Lung cancer ,Aged ,Retrospective Studies ,Performance status ,business.industry ,IO ,Eosinophil ,medicine.disease ,030104 developmental biology ,chemistry ,business ,Follow-Up Studies - Abstract
Background Second-line immunotherapy (IO) has shown an overall survival benefit. However, only 18% to 20% of patients with advanced non–small-cell lung cancer (aNSCLC) will respond, with a median progression-free survival (PFS) of 2 to 4 months. Thus, biomarkers to select those patients most likely to benefit from IO are greatly needed. Patients and Methods We conducted a retrospective analysis of 154 patients with aNSCLC who had received anti–programmed cell death 1 therapy as second line or further treatment. We assessed the absolute neutrophil, lymphocyte, monocyte, and eosinophil counts at baseline (T0) and the second (T1) and third (T2) cycles. The neutrophil/lymphocyte ratio (NLR), derived-NLR (dNLR), lymphocyte/monocyte ratio (LMR), and their percentage of change at T1 and T2 compared with T0 were evaluated. The clinical characteristics and lactate dehydrogenase (LDH) level were also considered. Univariate and multivariate analyses were performed. Significant biomarkers for PFS on multivariate analysis were combined in a prognostic score. Results For overall survival, the negative prognostic biomarkers were Eastern Cooperative Oncology Group (ECOG) performance status (PS) 2, NLR at T0, and dNLR at T1; the LMR at T0, T1, and T2 was identified as a positive prognostic biomarker. For PFS, the negative prognostic biomarkers were ECOG PS 2, liver metastases, NLR at T0, dNLR at T1 and T2, and ≥ 30% increase of NLR from T0 to T1; the positive prognostic biomarkers were heavy smoking, LDH, and LMR at T2. The ≥ 30% increase of LMR from T0 to T1 and T0 to T2 correlated with the overall response rate. A prognostic score (EPSILoN score; smoking, ECOG PS, liver metastases, LDH, NLR) identified 3 prognostic groups (median PFS, 10.2, 4.9, and 1.7 months, respectively; P Conclusions The EPSILoN score combines 5 baseline clinical and blood biomarkers and can help to identify patients with aNSCLC who will most likely benefit from second-line IO. Further studies are warranted.
- Published
- 2020
48. Final data of an Italian multicentric survey about counseling for smoking cessation in patients with diagnosis of a respiratory disease
- Author
-
Gian Piero Bandelli, M. Gianetta, Silvia Novello, Arianna Bruno, Sara Demichelis, M.V. Pacchiana, S.G. Rapetti, Stefania Vallone, G. Valmadre, Sara Pilotto, Anna Maria Moretti, Annamaria Catino, Rocco Trisolini, Emilio Bria, Enrica Capelletto, Domenico Galetta, and D. Ricci
- Subjects
Adult ,Male ,Pulmonary and Respiratory Medicine ,Chronic bronchitis ,medicine.medical_specialty ,Adolescent ,Referral ,medicine.medical_treatment ,Respiratory Tract Diseases ,Smoking Prevention ,COPD ,chronic bronchitis ,clinical respiratory medicine ,counseling ,lung cancer ,oncology ,smoking cessation ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Risk Factors ,Surveys and Questionnaires ,Health care ,medicine ,Humans ,Immunology and Allergy ,030212 general & internal medicine ,Lung cancer ,Genetics (clinical) ,Aged ,Retrospective Studies ,Nicotine replacement ,business.industry ,Smoking ,Respiratory disease ,Middle Aged ,Prognosis ,medicine.disease ,Italy ,030220 oncology & carcinogenesis ,Family medicine ,Physical therapy ,Smoking cessation ,Female ,Morbidity ,business ,Follow-Up Studies - Abstract
Introduction: Smoking is the major risk factor for cancer and several respiratory diseases. Quitting smoking at any point of life may increase the effectiveness of treatments and improve prognosis of patients with any pulmonary disease, including lung cancer. However, few institutions in Europe offer to patients adequate counseling for smoking cessation. Objectives: Aim of this study was to investigate the level of counseling for smoking cessation offered by healthcare professionals to patients and their appreciation towards the intervention itself. Methods: Between January 2013 and February 2016, 490 patients, diagnosed with a respiratory diseases, were prospectively evaluated with an anonymous survey developed by WALCE (Women Against Lung Cancer in Europe). Results: The majority of patients enrolled (76%) declared to have stopped smoking after the diagnosis of a respiratory disease, 17% to smoke less, 7% to continue smoking. Patients who reported to have never received any counseling for smoking cessation were 38%. Almost 73% of the other patients reported a positive judgment about the quality of healthcare's intervention. Despite these favorable considerations, 83% of patients have disclosed they simply quit smoking overnight without help, 5% have used electronic cigarettes, 5% nicotine replacement treatments, 4% dedicated books, 3% have attended a referral clinic. Conclusions: Considering all the smoking-related side effects, greater efforts should be made in order to better support patients in smoking cessation. Smoking should be considered as a real physical disorder and similar surveys should be encouraged with the aim to fight the “stigma” of smoking that still exists among patients. This article is protected by copyright. All rights reserved.
- Published
- 2018
49. EP1.04-38 A Case of Lichenoid Reaction as Late and Uncommon Immune-Related Skin Toxicity During Nivolumab Treatment
- Author
-
S. Strippoli, Annamaria Catino, R. Filannino, F. Pesola, G. Del Bene, Pamela Pizzutilo, Michele Montrone, M. Guida, Vito Longo, L. Fucci, and Domenico Galetta
- Subjects
Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,Skin toxicity ,Immune system ,Oncology ,business.industry ,Medicine ,Nivolumab ,business ,Dermatology - Published
- 2019
50. P2.10-06 Smoking Prevalence and Perceptions Among Healthcare Professionals: A Survey in an Italian Clinical Cancer Centre
- Author
-
D. Ricci, Michele Montrone, V. Lamorgese, P. Petrillo, Vito Longo, Pamela Pizzutilo, Domenico Galetta, Niccolò Varesano, A. Mastrandrea, Annamaria Catino, A. Zacheo, F. Pesola, and D. Bafunno
- Subjects
Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,Oncology ,Health professionals ,business.industry ,Family medicine ,Cancer centre ,Medicine ,Smoking prevalence ,business - Published
- 2019
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.